<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006689.pub2" GROUP_ID="INFECTN" ID="965006091511515410" MERGED_FROM="" MODIFIED="2012-08-02 10:43:28 +0100" MODIFIED_BY="Anne-Marie Stephani" REVIEW_NO="DMAT" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2012-08-02 10:41:18 +0100" MODIFIED_BY="Anne-Marie Stephani">
<TITLE>Intermittent preventive treatment regimens for malaria in HIV-positive pregnant women</TITLE>
<CONTACT>
<PERSON ID="222F3C6682E26AA201CB127872ABEE9D" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Don</FIRST_NAME>
<MIDDLE_INITIALS>P</MIDDLE_INITIALS>
<LAST_NAME>Mathanga</LAST_NAME>
<SUFFIX/>
<POSITION>Deputy Director</POSITION>
<EMAIL_1>dmathang@mac.medcol.mw</EMAIL_1>
<EMAIL_2>dmathanga@yahoo.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Malaria Alert Center, College of Medicine</DEPARTMENT>
<ORGANISATION>University of Malawi</ORGANISATION>
<ADDRESS_1>P/Bag 360</ADDRESS_1>
<ADDRESS_2>Chichiri</ADDRESS_2>
<CITY>Blantyre</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="MW">Malawi</COUNTRY>
<PHONE_1>+265 1670858</PHONE_1>
<PHONE_2>+265 1670145</PHONE_2>
<FAX_1>+265 1676217</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-08-02 10:40:30 +0100" MODIFIED_BY="Anne-Marie Stephani">
<PERSON ID="222F3C6682E26AA201CB127872ABEE9D" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Don</FIRST_NAME>
<MIDDLE_INITIALS>P</MIDDLE_INITIALS>
<LAST_NAME>Mathanga</LAST_NAME>
<SUFFIX/>
<POSITION>Deputy Director</POSITION>
<EMAIL_1>dmathang@mac.medcol.mw</EMAIL_1>
<EMAIL_2>dmathanga@yahoo.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Malaria Alert Center, College of Medicine</DEPARTMENT>
<ORGANISATION>University of Malawi</ORGANISATION>
<ADDRESS_1>P/Bag 360</ADDRESS_1>
<ADDRESS_2>Chichiri</ADDRESS_2>
<CITY>Blantyre</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="MW">Malawi</COUNTRY>
<PHONE_1>+265 1670858</PHONE_1>
<PHONE_2>+265 1670145</PHONE_2>
<FAX_1>+265 1676217</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="DC84C05982E26AA201BA4B543B94C67E" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Olalekan</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Uthman</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>uthlekan@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Evidence-Based Health Care</DEPARTMENT>
<ORGANISATION>Faculty of Health Sciences, Stellenbosch University</ORGANISATION>
<ADDRESS_1>Francie van Zijl drive</ADDRESS_1>
<ADDRESS_2>Tygerberg Campus</ADDRESS_2>
<CITY>Tygerberg</CITY>
<ZIP>7505</ZIP>
<REGION>Cape Town</REGION>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4B6E3CD282E26AA20129AA212CFEA6AB" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jobiba</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chinkhumba</LAST_NAME>
<SUFFIX/>
<POSITION>Scientist</POSITION>
<EMAIL_1>jchinkhumba@mac.medcol.mw</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Malaria Alert Center</DEPARTMENT>
<ORGANISATION>College of Medicine, University of Malawi</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Blantyre</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="MW">Malawi</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-02-03 09:47:27 +0000" MODIFIED_BY="David Sinclair">
<UP_TO_DATE>
<DATE DAY="12" MONTH="7" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="28" MONTH="6" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="6" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="10" YEAR="2011"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2012-08-02 10:41:18 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-08-02 10:41:18 +0100" MODIFIED_BY="Anne-Marie Stephani">
<DATE DAY="18" MONTH="7" YEAR="2012"/>
<DESCRIPTION>
<P>The GRADE assessments were adjusted in the summary of findings tables and the conclusions were modified in accordance with this.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-08-26 09:02:25 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-08-26 09:02:25 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Reviews for Africa Programme</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>South African Cochrane Centre</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>MPH Program, Department of Community Health, College of Medicine</NAME>
<COUNTRY CODE="MW">Malawi</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Malaria Alert Center</NAME>
<COUNTRY CODE="MW">Malawi</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Nuffield Commonwealth Foundation</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department for International Development (DFID)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-07-18 15:41:09 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-07-18 15:41:09 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Drugs to prevent malaria in HIV-positive pregnant women.</TITLE>
<SUMMARY_BODY MODIFIED="2012-07-18 15:41:09 +0100" MODIFIED_BY="[Empty name]">
<P>Intermittent preventive treatment is the administration of a complete curative dose of an antimalarial medicine at predefined intervals during pregnancy (from the second trimester) regardless of whether or not the pregnant woman has malaria parasites. Intermittent preventive treatment for pregnant women, as is delivered at routine ante-natal care visits, is a World Health Organization (WHO) recommended policy and has been adopted in the majority of African malaria endemic countries. Since HIV increases the severity of malaria in pregnant women, it is important to evaluate the various drugs and doses needed to prevent malaria in HIV-positive pregnant women.</P>
<P>This review only identified two trials which compared the impact of using three or more doses of sulphadoxine-pyrimethamine to using only two doses. Using three or more doses was more effective at preventing the presence of malaria parasites in the placenta and in the peripheral blood of the pregnant woman than using the standard two doses only. Also, children born to HIV-positive pregnant women who used three or more doses of sulphadoxine-pyrimethamine weighed more than those born to mothers who used only the standard two doses.</P>
<P>Although more frequent doses of this drug are effective in preventing malaria, HIV-positive pregnant women with low CD4 count can not use the drug since the current policy requires that they use co-trimoxazole (Bactrim®) to prevent opportunistic infections. There is need, therefore, to investigate alternative drugs and regimens in preventing malaria in HIV-positive pregnant women.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-07-18 15:38:38 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-09-02 09:00:41 +0100" MODIFIED_BY="[Empty name]">
<P>Intermittent preventive treatment is recommended for pregnant women living in malaria endemic countries due to benefits for both mother and baby. However, the impact may not be the same in HIV-positive pregnant women, as HIV infection impairs a woman's immunity.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-07-27 18:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>To compare intermittent preventive treatment regimens for malaria in HIV-positive pregnant women living in malaria-endemic areas.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-09-02 09:00:45 +0100" MODIFIED_BY="[Empty name]">
<P>In June 2011, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE; EMBASE; LILACS, the metaRegister of Controlled Trials (mRCT), reference lists and conference abstracts. We also contacted researchers and organizations for information on relevant trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-09-02 09:26:17 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials comparing different intermittent preventive treatment regimens for preventing malaria in HIV-positive pregnant women in malaria-endemic areas.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-09-02 09:00:48 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors extracted data and assessed risk bias. Dichotomous variables were combined using risk ratios (RR) and mean differences (MD) for continuous outcomes, both with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-07-18 15:38:38 +0100" MODIFIED_BY="[Empty name]">
<P>Two randomized trials were included, enrolling 722 HIV-positive pregnant women from Malawi and Zambia. Both compared monthly regimens of sulfadoxine-pyrimethamine (SP) to the standard 2-dose regimen given in the second and third trimesters.</P>
<P>In women in their first or second pregnancy, monthly SP may reduce both maternal parasitaemia (two trials, 463 participants, RR 0.25, 95% CI 0.14 to 0.43, <I>low quality evidence</I>), and placental parasitaemia at delivery (two trials, 459 participants, RR 0.38, 95% CI 0.21 to 0.70, <I>low quality evidence</I>). Monthly SP may have a small effect on the prevalence of maternal anaemia at delivery (two trials, 447 participants, RR 0.93, 95% CI 0.72 to 1.20, <I>low quality evidence</I>), and the number of babies born with low birth weight (two trials, 469 participants, RR 0.80, 95% CI 0.52 to 1.23, <I>low quality evidence</I>), but larger trials are necessary to reliably prove or exclude clinically important benefits on these outcomes. There is currently insufficient evidence to make conclusions regarding an effect on neonatal mortality (one study, 253 participants, <I>very low quality evidence</I>).</P>
<P>In women in their third or higher pregnancy, there is insufficient evidence to make any conclusions on the benefits of monthly SP compared to the two dose regimen (one trial, 166 participants, <I>very low quality evidence</I>).</P>
<P>There were no trials that assessed other treatment regimens for intermittent preventive treatment in HIV-positive pregnant women.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-07-18 15:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>Three or more doses of SP may have some advantages over the standard two doses in HIV-positive pregnant women, but larger trials would be necessary to confirm an effect on patient important outcomes. However, since SP cannot be administered concurrently with co-trimoxazole - a drug often recommended for infection prophylaxis in HIV-positive pregnant women, new drugs and research is needed to address needs of HIV-positive pregnant women.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-07-18 15:38:54 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-09-02 09:02:32 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-08-26 09:02:55 +0100" MODIFIED_BY="[Empty name]">
<P>Malaria is a leading cause of morbidity and mortality. An estimated 350 and 500 million clinical episodes of malaria occur each year, resulting in over one million deaths. Around 60% of the clinical cases and over 90% of the deaths occur in sub-Saharan Africa (<LINK REF="REF-Korenromp-2005" TYPE="REFERENCE">Korenromp 2005</LINK>). In addition to acute disease and deaths, malaria also contributes significantly to maternal anaemia during pregnancy and adverse birth outcomes such as spontaneous abortion, stillbirth, premature delivery, and low birthweight. Each year, 25 to 30 million pregnancies in the sub-Saharan region are at high risk of these adverse consequences of malaria (<LINK REF="REF-Chico-2008" TYPE="REFERENCE">Chico 2008</LINK>), with the first pregnancy and, to a lesser extent, the second being at highest risk (<LINK REF="REF-Cot-2003" TYPE="REFERENCE">Cot 2003</LINK>).</P>
<P>Sub-Saharan Africa is also home to an estimated 22.5 million adults and children living with the human immunodeficiency virus (HIV), with an estimated 1.3 million HIV-associated deaths in 2009 alone (<LINK REF="REF-UNAIDS-2010" TYPE="REFERENCE">UNAIDS 2010</LINK>). Most (55%) of those infected are women of reproductive age (<LINK REF="REF-Dabis-2002" TYPE="REFERENCE">Dabis 2002</LINK>), and HIV/AIDS is now an ever-increasing cause of maternal mortality. Although both malaria and HIV/AIDS have distinct risk factors for transmission, the two diseases are associated with poverty and share similar determinants of vulnerability to infection. Many of these determinants are present in sub-Saharan Africa. Malaria and HIV/AIDS therefore overlap geographically and target the same vulnerable populations in this region.<BR/>
<B>
<BR/>Interaction of HIV and malaria</B>
<BR/>Because of the high prevalence of malaria and HIV infection in the region, co-infection and interaction between the two diseases are very common (<LINK REF="REF-Abu_x002d_Raddad-2006" TYPE="REFERENCE">Abu-Raddad 2006</LINK>; <LINK REF="REF-Froebel-2004" TYPE="REFERENCE">Froebel 2004</LINK>; <LINK REF="REF-Korenromp-2005a" TYPE="REFERENCE">Korenromp 2005a</LINK>; <LINK REF="REF-Kublin-2005" TYPE="REFERENCE">Kublin 2005</LINK>). Evidence shows that HIV increases the risk of malaria infection (<LINK REF="REF-French-2001" TYPE="REFERENCE">French 2001</LINK>), high-density parasitaemia and clinical malaria (<LINK REF="REF-Whitworth-2000" TYPE="REFERENCE">Whitworth 2000</LINK>), severe malaria (<LINK REF="REF-Chalwe-2009" TYPE="REFERENCE">Chalwe 2009</LINK>) and malaria-related mortality (<LINK REF="REF-Malamba-2007" TYPE="REFERENCE">Malamba 2007</LINK>). Reports also suggest that antimalarial treatment failure may be more common in HIV-infected adults with low CD4-cell counts compared to those not infected with HIV (<LINK REF="REF-Van-Geertruyden-2006" TYPE="REFERENCE">Van Geertruyden 2006</LINK>). Acute malaria episodes are also associated with increased HIV plasma viral load (<LINK REF="REF-Kublin-2005" TYPE="REFERENCE">Kublin 2005</LINK>), although with no indication that the level of viral load is permanently modified. In pregnant women, HIV infection has also been shown to impair the ability of pregnant women to control<I> </I>infection with<I> Plasmodium falciparum</I>. HIV-positive pregnant women are more likely to have detectable parasitaemia, higher malaria parasite densities, and develop clinical or placental malaria and malarial anaemia than HIV-negative pregnant women ( <LINK REF="REF-ter-Kuile-2004" TYPE="REFERENCE">ter Kuile 2004</LINK>; <LINK REF="REF-Perrault-2009" TYPE="REFERENCE">Perrault 2009</LINK>). Although previous data suggested that placental malaria could increase the risk of HIV transmission from mother to child (<LINK REF="REF-Brahmbhatt-2003" TYPE="REFERENCE">Brahmbhatt 2003</LINK>), more recent data shows that this may not be the case (<LINK REF="REF-Msamanga-2009" TYPE="REFERENCE">Msamanga 2009</LINK>).Therefore the interaction between the two diseases makes the prevention of malaria in HIV-positive pregnant women a public health priority.</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-09-02 09:02:22 +0100" MODIFIED_BY="[Empty name]">
<P>To prevent malaria in pregnancy, the World Health Organization (WHO) recommends that all women living in sub-Saharan Africa promptly treat malaria using effective antimalarials, receive intermittent preventive treatment during pregnancy (IPTp) and use long lasting insecticide-treated nets (LLINs) every night (<LINK REF="REF-WHO-2004" TYPE="REFERENCE">WHO 2004</LINK>). IPTp is given once during the second and third trimester of the pregnancy. Chloroquine and sulfadoxine-pyrimethamine (SP) are the safest and most readily available and affordable drugs for the prevention of malaria in pregnancy in most African countries (<LINK REF="REF-Garner-2006" TYPE="REFERENCE">Garner 2006</LINK>). However, the efficacy of these drugs is decreasing in many African countries due to drug resistance. Malaria treatment and prevention may not be the same in HIV-positive pregnant women as is the case with HIV-negative pregnant women. In western Kenya, the usual IPTp schedule of two doses of SP was suboptimal among HIV-positive women in their first and second pregnancies. Since then more studies comparing three or more SP doses to the two-dose policy have been commissioned and carried out in HIV-positive pregnant women. Also, because of the deteriorating efficacy of SP, other drugs such as amodiaquine (<LINK REF="REF-Tagbor-2006" TYPE="REFERENCE">Tagbor 2006</LINK>) and drug combination regimens (including artemisinin derivatives) are being evaluated to assess their impact in preventing or treating malaria in pregnancy. However, the overall impact of these drugs or drug regimens will have to be assessed for HIV-positive pregnant women.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2011-09-02 09:02:32 +0100" MODIFIED_BY="[Empty name]">
<P>HIV testing is the first step in accessing tailor-made care for HIV-positive pregnant women and their unborn babies. Unfortunately, in developing countries only few pregnant women have access to prevention of mother-to-child transmission services (<LINK REF="REF-WHO-2010a" TYPE="REFERENCE">WHO 2010a</LINK>). Nonetheless, gradual but important progress to increase access to HIV-related care for pregnant women is being made in sub-Saharan countries (<LINK REF="REF-WHO-2010a" TYPE="REFERENCE">WHO 2010a</LINK>). For example, most countries have HIV national policies that not only include treatment care and support but also a prevention of mother-to-child transmission component. For HIV-positive pregnant women, this package of care includes access to antiretroviral treatment, co-trimoxazole prophylaxis, nutritional counselling, and support. Increasing linkages between prevention of mother-to-child transmission programmes with other programmes, such as malaria control, has also led to preferential targeting of HIV-positive pregnant women with insecticide-treated nets.</P>
<P>The aim of this systematic review is to assess the impact of IPTp in HIV-positive pregnant women in the context of the currently available health care packages.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-09-02 09:02:34 +0100" MODIFIED_BY="[Empty name]">
<P>To compare IPTp regimens for malaria in HIV-positive pregnant women.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-07-18 15:18:37 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-07-18 15:08:36 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-09-02 09:02:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>HIV-positive pregnant women living in regions in which there is stable transmission of <I>P. falciparum</I>.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-08-26 10:17:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Intervention</B>
</I>
<B>
<BR/>
</B>
</P>
<UL>
<LI>Sulfadoxine-pyrimethamine: three or more doses (25 mg/kg sulphadoxine and 1.25 mg/kg pyrimethamine) during the second and third trimester.</LI>
<LI>Other antimalarial drug(s): regimen specific to this population.</LI>
</UL>
<P>
<B>Control<BR/>
</B>
</P>
<UL>
<LI>Sulfadoxine-pyrimethamine (as above): two doses.</LI>
<LI>Other antimalarial drug(s): standard regimen.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-07-18 15:08:36 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary</HEADING>
<UL>
<LI>Maternal anaemia: measured as maternal haemoglobin levels &lt; 11 g/dL at delivery.</LI>
<LI>Low birthweight: measured as birthweight &lt; 2.5 kg in singleton.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary</HEADING>
<UL>
<LI>Maternal and neonatal mortality.</LI>
<LI>Placental malaria: measured by the presence of malaria in the placenta.</LI>
<LI>Peripheral parasitaemia: measured by the presence of malaria parasites on thick and thin malaria smears.</LI>
<LI>Birthweight.</LI>
<LI>Maternal haemoglobin levels.</LI>
<LI>Maternal viral load: measured as number of HIV-RNA copies/mL.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<UL>
<LI>Serious adverse events (fatal, life threatening, or those that require hospitalization).</LI>
<LI>Adverse events leading to discontinuation of intervention.</LI>
<LI>Other adverse events.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-09-02 09:03:32 +0100" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<SUBSECTION>
<HEADING LEVEL="3">Databases</HEADING>
<P>On 28 June 2011, we searched the following databases using the search terms and strategy in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>: Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL), published in <I>The Cochrane Library</I>; MEDLINE; EMBASE; and LILACS. We also searched the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) using the terms: malaria, HIV, and pregnan*.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Conference proceedings</HEADING>
<P>We searched the following conference proceedings for trial information: The Multilateral Initiative on Malaria Pan-African Conference (Yaoundé 2005, Nairobi 2009); American Society for Tropical Medicine and Hygiene Conference (yearly from 2000 to 2009); and International AIDS Conference (Barcelona, 2002; Bangkok 2004, Toronto 2006, Mexico city 2008 and Vienna 2010); 8th International Conference on Drug Therapy in HIV Infection, Glasgow 2006; 3rd International Aids Society Pathogenesis and Treatment Conference, Rio de Janeiro 2005.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Researchers</HEADING>
<P>We contacted researchers working in malaria and competent authorities in HIV/malaria to ask about relevant ongoing studies or unpublished work.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Organizations</HEADING>
<P>We contacted the following organization for information on ongoing studies: World Health Organization; Special Programme for Research and Training in Tropical Diseases; Joint United Nations Programme on HIV/AIDS (June 2010); and European and Developing Countries Clinical Trials Partnership (June 2010).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Reference lists</HEADING>
<P>We checked the reference lists of all identified trials and relevant narrative reviews for other potentially relevant trials.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-07-18 15:18:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-07-29 09:11:05 +0100" MODIFIED_BY="[Empty name]">
<P>The eligibility of the studies were judged independently by two review authors by going through all the abstracts identified in the above searches. For each potentially relevant abstract, a full study report was found and the inclusion criteria applied independently by the review authors using a standard eligibility form. Where disagreements arose, the review authors reached a consensus through discussion. Excluded studies were listed and the reasons for exclusion stated.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-07-18 15:18:37 +0100" MODIFIED_BY="[Empty name]">
<P>The review authors independently extracted data from the trial reports using a pre-tested data extraction form. For dichotomous variables, the review authors extracted data on the total number of participants randomized, number that experienced these outcomes, and the number analysed. For continuous outcomes, data on the total number of participants analysed, arithmetic means, standard deviation (SD), and the number of participants randomized were extracted. Where only standard error (SE) was reported, standard deviation was calculated using the following formula: SD = SE x square root of N.</P>
<P>Data was double-entered into <LINK REF="REF-Review-Manager-5.0" TYPE="REFERENCE">Review Manager 5.0</LINK> for analysis.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-09-02 09:03:44 +0100" MODIFIED_BY="[Empty name]">
<P>The risk of bias was independently assessed by the review authors using six factors: generation of allocation sequence, allocation concealment, blinding, intention-to- treat analysis (incomplete outcome data), selective reporting and presence of other biases. Generatation of the allocation sequence and allocation concealment a judgement of yes, no or unclear to was given to represent a low, high or unclear risk of bias. Blinding was assessed based on which parties (study participant, care provider, or assessor) were blinded to the treatment and control arms of the study. We also assessed whether issues around incomplete outcome data were addressed (intention-to-treat analysis), whether there was selective reporting of the results and the presence of other biases in the trials. We intended to explore the presence of reporting biases using funnel plots but were unable to do so due to the nature of the data. Disagreements between the review authors were resolved through discussions.</P>
</QUALITY_ASSESSMENT>
<MISSING_DATA MODIFIED="2011-07-29 09:11:31 +0100" MODIFIED_BY="[Empty name]">
<P>The impact of missing data on the study results was explored with a sensitivity analysis comparing the results from the analyses of study completers (complete cases) with those from best- and worst-case scenarios.</P>
</MISSING_DATA>
<DATA_SYNTHESIS MODIFIED="2011-09-02 09:04:16 +0100" MODIFIED_BY="[Empty name]">
<P>Meta-analyis was conducted in <LINK REF="REF-Review-Manager-5.0" TYPE="REFERENCE">Review Manager 5.0</LINK>. Occurrence of the specified outcomes was compared between participants that received monthly IPTp using SP and those that received a standard 2-dose SP. Risk ratios (RR) and mean differences were calculated for dichotomous and continuous variables respectively. For continuous data, where arithmetic means, SDs,or SEs are reported, we compared the means within trials to calculate a mean difference. All results were presented with 95% confidence intervals (CI).</P>
<P>Heterogeneity amongst the trials was assessed by visually inspecting the forest plots and using the Chi<SUP>2</SUP> test (with P value &lt; 0.1 representing heterogeneity), and the I<SUP>2</SUP> statistic (I<SUP>2</SUP>
<I> </I>&gt; 50% considered as substantial heterogeneity).</P>
<P>For dichotomous measures, three analyses were undertaken:</P>
<UL>
<LI>Complete case: participants with missing outcomes were excluded (as report by trial authors), data on only those whose results are known, using as denominator the total number of patients who completed the trial.</LI>
<LI>Best-case scenario: all participants in monthly SP with missing were assumed to had good outcomes and all participants in 2&#8211;dose SP with missing outcomes were assumed to had poor outcomes</LI>
<LI>Worst-case scenario: all participants in monthly-SP with missing were assumed to had poor outcomes and all participants in 2-dose SP with missing outcomes were assumed to had good outcomes.</LI>
</UL>
<P>For continuous outcomes, we used complete case analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-07-29 09:11:41 +0100" MODIFIED_BY="[Empty name]">
<P>As part of the primary analysis, subgroup analysis was conducted based on the number of pregnancies.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-07-18 15:29:58 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-09-02 09:05:12 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Study selection</HEADING>
<P>Two trials were identified as fulfilling the inclusion criteria, one published (<LINK REF="STD-Filler-2006" TYPE="STUDY">Filler 2006</LINK>) and the other identified through conference abstracts (<LINK REF="STD-Hamer-2007" TYPE="STUDY">Hamer 2007</LINK>); details of these trials are shown in the "<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>" section. One more trial (<LINK REF="REF-Parise-1998" TYPE="REFERENCE">Parise 1998</LINK>) was excluded and the details of exclusion are included in the "<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>" table.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trial location</HEADING>
<P>
<LINK REF="STD-Filler-2006" TYPE="STUDY">Filler 2006</LINK> was conducted in rural Malawi and <LINK REF="STD-Hamer-2007" TYPE="STUDY">Hamer 2007</LINK> was conducted in an urban locale of Zambia. In both countries, transmission of <I>P. falciparum </I>is considered stable. However, in both countries there is an high level of resistance of <I>P. falciparum</I> to SP (<LINK REF="REF-Malenga-2009" TYPE="REFERENCE">Malenga 2009</LINK>; <LINK REF="REF-Bijl-2000" TYPE="REFERENCE">Bijl 2000</LINK>; <LINK REF="REF-Mulenga-2006" TYPE="REFERENCE">Mulenga 2006</LINK>), with both Zambia and Malawi changing to artemisinin combination therapy for malaria treatment in 2002 and 2007, respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>
<LINK REF="STD-Filler-2006" TYPE="STUDY">Filler 2006</LINK> included 266 HIV-positive pregnant women in their first or second pregnancies whilst <LINK REF="STD-Hamer-2007" TYPE="STUDY">Hamer 2007</LINK> included 456 HIV-positive pregnant women regardless of their gravida status. HIV testing was performed using rapid diagnostic tests in parallel: <LINK REF="STD-Filler-2006" TYPE="STUDY">Filler 2006</LINK> used Uni-Gold (Trinity Biotech) and Determine (Abbott Laboratories); and <LINK REF="STD-Hamer-2007" TYPE="STUDY">Hamer 2007</LINK> used Determine (Abbott Laboratories) and Capillus (Cambridge Biotech Ltd). <LINK REF="STD-Filler-2006" TYPE="STUDY">Filler 2006</LINK> further evaluated discordant results using Hema Strip HIV (Saliva Diagnostic Systems) and <LINK REF="STD-Hamer-2007" TYPE="STUDY">Hamer 2007</LINK> used Bionor assay (Skien, Norway). A HemoCue machine was used to measure haemoglobin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intervention</HEADING>
<P>Both studies compared the impact of monthly SP, with directly observed treatment doses at enrolment and then monthly until delivery to the standard WHO recommendation of 2-doses of SP, with directly observed treatment doses at enrolment and the other dose in the third trimester. There were no trials that looked at other treatment regimens for IPTp.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>Placental malaria was the primary outcome in both studies. Both studies collected information on maternal anaemia, peripheral parasitaemia, placental parasitaemia, maternal haemoglobin, birth weight, low birth weight (LBW), premature births, severe adverse drug reaction and uncomplicated malaria. Placental parasitaemia was defined as the presence of asexual-stage parasites in thick smears using maternal-side placental blood. Parasitaemia (in peripheral or cord blood) was defined as the presence of asexual-stage parasites in thick smears. Newborns weighing &lt;2.5 kg were classified as low birth weight. Women with haemoglobin levels of &lt;11 g/dL were considered anaemic and severe ADRs were defined as erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis. <LINK REF="STD-Hamer-2007" TYPE="STUDY">Hamer 2007</LINK> included histological evidence of placental malaria documented through examination of placental biopsies. See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for a summary of outcomes.</P>
</SUBSECTION>
<SEARCH_RESULTS MODIFIED="2011-09-02 09:05:12 +0100" MODIFIED_BY="[Empty name]">
<P>During the search, 19 published studies were identified. Three potentially eligible studies were identified, of which two met the inclusion criteria and one was excluded.</P>
<P>All the included studies are published in English and were conducted in malaria endemic sub-Saharan African countries. Not all patients reported in the included studies contributed to this review: one study included HIV-positive and HIV-negative pregnant women. Only the HIV-positive pregnant women were included in the review.</P>
</SEARCH_RESULTS>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-09-02 09:05:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Filler-2006" TYPE="STUDY">Filler 2006</LINK> randomly assigned trial participants to the intervention or control arm through permuted blocks of random length. However, it is unclear how allocation concealment was achieved. Neither study participants nor the investigators were blinded to group assignment. Only the laboratory workers, who assessed the primary outcome of placental parasitaemia, were blinded to the women's HIV status and treatment arm. The investigators state that an intention to treat analysis was performed; however, data presented in the trial report were based on the number of participants whose data were available. This trial was stopped at the interim analysis due to significant differences between the two treatment regimens.</P>
<P>For <LINK REF="STD-Hamer-2007" TYPE="STUDY">Hamer 2007</LINK>, trial participants were randomized in blocks of 20 to either the treatment or control arm. Participants were then assigned sequential ID numbers during enrolment corresponding to a sealed package of study drugs. The randomization codes were retained by the study statistician and stored in a locked cabinet at Boston University. The code was broken when data collection was complete and preliminary blinded analyses had been performed. Study subjects, the investigators and the assessors were blinded to the trial arm allocation. Intention to treat analysis was not performed.</P>
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for a summary of the assessment of risk bias.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-07-18 15:29:58 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Monthly SP compared to a standard 2-dose regimen</HEADING>
<P>The two included trials only compared monthly SP to the recommended 2-dose SP in the second and third trimesters. There were no trials that assessed other treatment regimens for IPTp in this population. The following results are therefore based on comparison of monthly SP to 2-dose SP in HIV-positive pregnant women.</P>
<SUBSECTION>
<HEADING LEVEL="4">Maternal anaemia</HEADING>
<P>The results from the two RCTs show that there was no statistically significant differences between monthly and 2-dose SP treatment groups in rates of maternal anaemia (RR 0.97, 95% CI 0.84 to 1.12, 604 participants, two trials) with evidence of no statistically significant heterogeneity (I<SUP>2 </SUP>= 18%, Chi<SUP>2</SUP> = 2.44, P = 0.30) (see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). There were no differences in rates of maternal anaemia in both subgroups (primi- / secundigravidae and multigravidae).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Low birth weight</HEADING>
<P>There was no statistically significant difference between the two treatment groups in rates of low birth weight (RR 0.88, 95% CI 0.59 to 1.32, 624 participants, two trials) with evidence of no statistically significant heterogeneity (I<SUP>2 </SUP>= 15%, Chi<SUP>2</SUP> = 2.36, P = 0.31) (see <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). There were no differences in rates of low birth weight among the two subgroups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Neonatal mortality</HEADING>
<P>Both trials reported neonatal mortality as an outcome. However, results for <LINK REF="STD-Hamer-2007" TYPE="STUDY">Hamer 2007</LINK> were not stratified by gravidity. <LINK REF="STD-Hamer-2007" TYPE="STUDY">Hamer 2007</LINK> reported that children born to mothers on monthly SP were 2.79 (95% CI 0.75 to 10.37, 640 participants, two trials) times more likely to die during the neonatal period than children from mothers on 2-dose SP (see <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), although the difference was not statistically different. <LINK REF="STD-Filler-2006" TYPE="STUDY">Filler 2006</LINK> on the other hand, showed fewer neonatal death in the monthly SP group than the 2-dose SP group, even though the difference was not statistically different (RR 0.29; 95% CI 0.08 to 1.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Placental parasitaemia</HEADING>
<P>There was a 58% reduction in risk of placental parasitaemia in women on monthly SP compared to those on 2-dose SP (RR 0.42; 95% CI 0.23 to 0.76, 612 participants, two trials) with evidence of no statistically significant heterogeneity (I<SUP>2 </SUP>= 0%, Chi<SUP>2</SUP> = 1.63, P = 0.44) (see <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). On subgroup analysis, this reduction in risk of placental parasitaemia was only significant among primigravidae and secundigravida (RR 0.38, 95% CI 0.21 to 0.70) and not in multigravidas (RR 1.87, 95% CI 0.17 to 20.23).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Peripheral parasitaemia</HEADING>
<P>The proportion of women on monthly SP who had peripheral parasitaemia was significantly lower than those on 2-dose SP (RR 0.26; 95% CI 0.15 to 0.45, 622 participants, two trials) with evidence of no statistical significant heterogeneity (I<SUP>2 </SUP>= 0%, Chi<SUP>2</SUP> = 0.85, P = 0.65) (see <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). On subgroup analysis, this reduction in risk of peripheral parasitaemia was only significant among primigravidae and secundigravida (RR 0.25, 95% CI 0.14 to 0.43) and not in multigravidas (RR 0.94; 95% CI 0.06 to 14.75)<B>. </B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Birth weight</HEADING>
<P>Babies born to women on monthly SP had a higher mean birth weight (weighted mean difference (WMD) 100g; 95% CI 90 g to 110 g, 640 participants, two trials) than babies born to mothers on 2-dose SP with evidence of substantial statistical significant heterogeneity (I<SUP>2 </SUP>= 98%, Chi<SUP>2</SUP> = 121.02, P &lt; 0.00001) (see <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). On subgroup analysis, this means birth weight was only was only significant higher among primigravidae and secundigravida (WMD 130 g; 95% CI 120 g to 150 g) and not in multigravidas (WMD 10 g; 95% CI -10 g to 30 g).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Maternal haemoglobin</HEADING>
<P>Women treated with monthly SP had significant higher haemoglobin level than those treated with treated 2 dose SP (WMD 0.18 g/dL, 95% CI 0.13 g/dL to 0.24 g/dL, 640 participants, two trials) with evidence of statistically significant moderate heterogeneity (I<SUP>2 </SUP>= 59%, Chi<SUP>2 </SUP>= 4.92, P = 0.09) (see <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). On subgroup analysis, this was only significant among multigravidae.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Maternal viral load</HEADING>
<P>None of the studies assessed the impact of monthly SP on HIV parameters. Hence, maternal viral load was not measured in both trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse Drug Reactions (ADR)</HEADING>
<P>Both trials reported on adverse events experienced by the mothers and neonates. <LINK REF="STD-Filler-2006" TYPE="STUDY">Filler 2006</LINK> did not report any severe cutaneous ADRs and in no case was SP withheld because of ADR concerns. Less than 1% of the women reported ADRs such as rash, nausea, vomiting, fever and &lt;0.4% of the newborns had neonatal jaundice. However, according to the authors, the differences in the proportion of women and neonates with ADRs in the standard 2-dose and monthly SP arms were not statistically different (data not provided by the trial). There was one neonatal death of a newborn with jaundice, born to an HIV-positive mother in the standard 2-dose SP. However, this death was attributed to prematurity (30 weeks of gestation) and a low birth weight of &lt; 1 kg.</P>
<P>
<LINK REF="STD-Hamer-2007" TYPE="STUDY">Hamer 2007</LINK> reports that one mother who received monthly SP died of presumed Stevens-Johnson syndrome. However, the trial authors report that the rates for serious and mild adverse events reported by mothers were low and did not differ between the study groups. There was only one case of neonatal jaundice in the monthly SP group and none in the 2-dose SP group. See <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> for details of ADRs across the trials.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Maternal anaemia</HEADING>
<P>The rates of maternal anaemia were sensitive to the allocation of withdrawals or post-randomization exclusions. Best-case scenarios produced larger effect size, but the 95% CI includes no effect (RR 0.66, 95% CI 0.38 to 1.16) (see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The worst case scenario produced statistically significant opposite result, such that women treated with monthly-SP were more likely to have had maternal anaemia compared to those women treated with 2-dose SP (RR 1.32, 95% CI 1.05 to 1.66) (see <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Low birth weight</HEADING>
<P>The rates of low birth weight were sensitive to the allocation of withdrawals or post-randomization exclusions, because there were considerable differences in the pooled estimates. Best-case scenario showed that monthly-SP was more effective than 2-dose SP in preventing low birth weight (RR 0.43, 95% CI 0.24 to 0.77) (see <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). While worst-case scenarios showed no difference between the two treatment groups (RR 1.91, 95% CI 0.85 to 4.38) (see <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Neonatal mortality</HEADING>
<P>The results of neonatal mortality were sensitivity to the allocation of withdrawals (see <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Placental parasitaemia</HEADING>
<P>Best-case scenario produced similar (but larger effect size) result to that of pooled result from complete case (RR 0.14, 95% CI 0.05 to 0.39) (see <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). Worst-case scenario showed no statistically significant difference between the two treatment groups (RR 3.24, 95% CI 0.35 to 30.02) (see <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Peripheral parasitaemia</HEADING>
<P>While result of best-case scenario (RR 0.14, 95% CI 0.04 to 0.33) was similar to that of complete case (see <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>), worst scenario produced no statistically significant difference in rates of peripheral parasitaemia (RR 2.22, 95% CI 0.25 to 20.15) (see <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-07-18 15:38:54 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-07-18 15:38:54 +0100" MODIFIED_BY="[Empty name]">
<P>Two randomized trials were included, enrolling 722 HIV-positive pregnant women from Malawi and Zambia. Both compared monthly regimens of SP to the standard 2-dose regimen given in the second and third trimesters.</P>
<P>In women in their first or second pregnancy, monthly SP may reduce both maternal parasitaemia (<I>low quality evidence</I>), and placental parasitaemia at delivery (<I>low quality evidence</I>). Monthly SP may have a small effect on the prevalence of maternal anaemia at delivery (<I>low quality evidence</I>), and the number of babies born with low birth weight (<I>low quality evidence</I>), but larger trials are necessary to reliably prove or exclude a clinically important benefit on these outcomes. There is currently insufficient evidence to make conclusions regarding an effect on neonatal mortality (<I>very low quality evidence</I>).</P>
<P>In women in their third or higher pregnancy, there is insufficient evidence to make any conclusions on the benefits of monthly SP compared to the two dose regimen (<I>very low quality evidence</I>).</P>
<P>There were no trials that assessed other treatment regimens for intermittent preventive treatment in HIV-positive pregnant women.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-07-18 15:13:25 +0100" MODIFIED_BY="[Empty name]">
<P>The review identified only two trials related to IPTp regimens for malaria in HIV-positive pregnant women. One study was conducted in the urban setting whilst the other was done in the rural area and all the studies involved the use of three or more doses of SP during the second and third trimester of pregnancy compared to use of only two doses of SP. No studies of other antimalarial drugs for IPTp in HIV-positive pregnant women were identified.</P>
<P>Findings reported by <LINK REF="STD-Filler-2006" TYPE="STUDY">Filler 2006</LINK> shows that the use of three or more doses was more beneficial in the rural setting than it was in the urban setting (<LINK REF="STD-Hamer-2007" TYPE="STUDY">Hamer 2007</LINK>). The low transmission in the urban area coupled with expansion of LLINs and indoor residual spraying (IRS) (<LINK REF="STD-Hamer-2007" TYPE="STUDY">Hamer 2007</LINK>) might have led to lower prevalence of some of the end points which in turn meant that the study lacked power to detect the changes.</P>
<P>Both trials did not report any significant differences in ADRs between those that received three or more doses compared to those that only received two doses. Whilst this is encouraging, the trials did not address the safety of concurrent administration of SP and co-trimoxazole in HIV-positive patients since the WHO now recommends daily prophylaxis with co-trimoxazole for symptomatic HIV-positive pregnant women or HIV-positive pregnant women with low CD4 count (cell count of &lt; 350 cells/mm<SUP>3</SUP>) (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>). Because concurrent use of SP and co-trimoxazole may increase the incidence of severe ADRs, co-trimoxazole only is recommended for prevention of malaria in HIV-positive pregnant women who are eligible for co-trimoxazole prophylaxis.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-07-18 15:32:28 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of the evidence was assessed using the GRADE methodology and the basis for the judgements is presented in two 'Summary of findings' tables (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). Low and very low quality evidence reflect increasing uncertainty in the result and a greater need for further research.</P>
<P>The two studies report the available case analysis. As imputation of missing data in order to perform a full intention-to-treat analysis is controversial, we considered the possible effects of the missing participants through sensitivity analyses. The 'Cochrane Handbook for Systematic Reveiws of Interventions' suggests that &#8220;a sensible decision in most cases is to include data for only those participants whose results are known, and discuss the potential impact of the missing data&#8221; (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Our best-case and worst-case imputation for intention-to-treat analyses showed a high sensitivity to post-randomization exclusions. We found evidence that missing data had substantial influence on the pooled results, as there were large differences between complete cases, best-case and worst-case scenarios for every outcome.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-08-26 09:06:31 +0100" MODIFIED_BY="[Empty name]">
<P>We were able to identify all relevant studies and obtain all relevant data. It is unlikely that the methods used in the review could have introduced bias.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-08-26 09:06:31 +0100" MODIFIED_BY="[Empty name]">
<P>To the best of our no knowledge, there are no other reviews to compare with this Cochrane Review.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-07-18 15:15:41 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-07-18 15:14:36 +0100" MODIFIED_BY="[Empty name]">
<P>Three or more doses of SP may have some advantages over the standard two doses in HIV-positive pregnant women, but larger trials would be necessary to confirm an effect on patient important outcomes. However, since SP cannot be administered concurrently with co-trimoxazole - a drug often recommended for infection prophylaxis in HIV-positive pregnant women - new drugs and research is needed to address needs of HIV-positive pregnant women.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-07-18 15:15:41 +0100" MODIFIED_BY="[Empty name]">
<P>Apart from SP, this review did not find any other regimens to prevent malaria in HIV-positive pregnant women. Since SP can not be administered concurrently with co-trimoxazole, its important that the safety and efficacy of other antimalarials be studied in HIV-positive pregnant women, especially now that resistance to SP is high in many malaria endemic countries. It is also important to study the efficacy of using co-trimoxazole in preventing malaria in HIV-postive pregnant women. Recent data from Malawi suggests that daily co-trimoxazole is more effective at reducing malaria infections and anaemia compared with IPTp using SP in HIV-positive pregnant women (<LINK REF="REF-Kapito_x002d_Tembo-2011" TYPE="REFERENCE">Kapito-Tembo 2011</LINK>). However, there is need to collaborate these findings in other settings through more robust methodologies.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-09-02 09:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>Don P. Mathanga was awarded a Reviews for Africa Programme Fellowship (www.mrc.ac.za/cochrane/rap.htm), funded by a grant from the Nuffield Commonwealth Programme, through The Nuffield Foundation. The editorial base for the Cochrane Infectious Diseases Group is funded by the UK Department for International Development (DFID) for the benefit of low- and middle-income countries.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-10-20 14:57:29 +0100" MODIFIED_BY="[Empty name]">
<P>None known for both authors.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-10-20 14:56:27 +0100" MODIFIED_BY="[Empty name]">
<P>Both authors have contributed to the development of the protocol, selection of studies, and analysis and interpretation of the data.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-09-05 11:58:46 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-09-02 09:08:36 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-09-02 09:08:36 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Filler-2006" NAME="Filler 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Filler S, Kazembe P, Thigpen M, Macheso A, Parise M, Newman R, et al</AU>
<TI>Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2006</YR>
<VL>194</VL>
<NO>3</NO>
<PG>286-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamer-2007" MODIFIED="2011-09-02 09:08:36 +0100" MODIFIED_BY="[Empty name]" NAME="Hamer 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-09-02 09:08:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hamer D, Mwanakasale V, MacLeod W, Chalwe V, Mukwamataba D, Champo D et al</AU>
<TI>Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2007</YR>
<VL>196</VL>
<NO>11</NO>
<PG>1585-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-11-12 13:20:39 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-12 13:20:39 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00270530"/>
</IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Parise-1998" NAME="Parise 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parise M, Ayisi J, Nahlen B, Schultz L, Roberts J, Misore A, et al</AU>
<TI>Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>5</NO>
<PG>813-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2010-11-30 06:28:43 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Korukiiko" MODIFIED="2010-11-30 06:24:43 +0000" MODIFIED_BY="[Empty name]" NAME="Korukiiko" YEAR="">
<IDENTIFIERS MODIFIED="2010-11-30 06:24:43 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-30 06:24:43 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00132535"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Macarthur" MODIFIED="2010-11-30 06:28:43 +0000" MODIFIED_BY="[Empty name]" NAME="Macarthur" YEAR="">
<IDENTIFIERS MODIFIED="2010-11-30 06:28:43 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-30 06:28:43 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00164255"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Manyando" MODIFIED="2010-11-12 14:55:01 +0000" MODIFIED_BY="[Empty name]" NAME="Manyando" YEAR="2010">
<IDENTIFIERS MODIFIED="2010-11-12 14:55:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-12 14:55:01 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01053325"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-09-05 11:58:46 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-09-05 11:58:46 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abu_x002d_Raddad-2006" MODIFIED="2011-09-02 09:08:46 +0100" MODIFIED_BY="[Empty name]" NAME="Abu-Raddad 2006" TYPE="JOURNAL_ARTICLE">
<AU>Abu-Raddad LJ, Patnaik P, Kublin JG</AU>
<TI>Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa</TI>
<SO>Science</SO>
<YR>2006</YR>
<VL>314</VL>
<NO>5805</NO>
<PG>1603-6</PG>
<IDENTIFIERS MODIFIED="2011-08-26 12:07:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Bijl-2000" MODIFIED="2011-09-02 09:09:09 +0100" MODIFIED_BY="[Empty name]" NAME="Bijl 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bijl HM, Kager J, Koetsier DW, van der Werf TS</AU>
<TI>Chloroquine- and sulfadoxine-pyrimethamine-resistant Falciparum malaria in vivo - a pilot study in rural Zambia</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2000</YR>
<VL>5</VL>
<NO>10</NO>
<PG>692-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brahmbhatt-2003" NAME="Brahmbhatt 2003" TYPE="JOURNAL_ARTICLE">
<AU>Brahmbhatt H, Kigozi G, Wabwire-Mangen F, Serwadda D, Sewankambo N, Lutalo T, et al</AU>
<TI>The effects of placental malaria on mother-to-child HIV transmission in Rakai, Uganda</TI>
<SO>AIDS</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>17</NO>
<PG>2539-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalwe-2009" MODIFIED="2011-09-02 09:08:57 +0100" MODIFIED_BY="[Empty name]" NAME="Chalwe 2009" TYPE="JOURNAL_ARTICLE">
<AU>Chalwe V, Van geertruyden JP, Mukwamataba D, Menten J, Kamalamba J, Mulenga M, et al</AU>
<TI>Increased risk for severe malaria in HIV-1-infected adults, Zambia</TI>
<SO>Emerging Infectious Diseases</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>5</NO>
<PG>749</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chico-2008" MODIFIED="2011-09-02 09:09:18 +0100" MODIFIED_BY="[Empty name]" NAME="Chico 2008" TYPE="JOURNAL_ARTICLE">
<AU>Chico RM, Pittrof R, Greenwood B, Chandramohan D</AU>
<TI>Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy</TI>
<SO>Malaria Journal</SO>
<YR>2008</YR>
<VL>7</VL>
<PG>255</PG>
<IDENTIFIERS MODIFIED="2011-08-26 12:07:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Cot-2003" MODIFIED="2011-09-02 09:09:28 +0100" MODIFIED_BY="[Empty name]" NAME="Cot 2003" TYPE="JOURNAL_ARTICLE">
<AU>Cot M, Deloron P</AU>
<TI>Malaria prevention strategies</TI>
<SO>British Medical Bulletin</SO>
<YR>2003</YR>
<VL>67</VL>
<PG>137-48</PG>
<IDENTIFIERS MODIFIED="2011-08-26 12:08:33 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Dabis-2002" NAME="Dabis 2002" TYPE="JOURNAL_ARTICLE">
<AU>Dabis F, Ekpini ER</AU>
<TI>HIV-1/AIDS and maternal and child health in Africa</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<NO>9323</NO>
<PG>2097-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-French-2001" NAME="French 2001" TYPE="JOURNAL_ARTICLE">
<AU>French N, Nakiyingi J, Lugada E, Watera C, Whitworth JA, Gilks CF</AU>
<TI>Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults</TI>
<SO>AIDS</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>7</NO>
<PG>899-906</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Froebel-2004" MODIFIED="2011-09-02 09:09:39 +0100" MODIFIED_BY="[Empty name]" NAME="Froebel 2004" TYPE="JOURNAL_ARTICLE">
<AU>Froebel K, Howard W, Schafer JR, Howie F, Whitworth J, Kaleebu P, et al</AU>
<TI>Activation by malaria antigens renders mononuclear cells susceptible to HIV infection and re-activates replication of endogenous HIV in cells from HIV-infected adults</TI>
<SO>Parasite Immunology</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>5</NO>
<PG>213-7</PG>
<IDENTIFIERS MODIFIED="2011-08-26 12:08:45 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Garner-2006" MODIFIED="2011-08-26 12:10:24 +0100" MODIFIED_BY="[Empty name]" NAME="Garner 2006" TYPE="COCHRANE_REVIEW">
<AU>Garner P, Gülmezoglu AM</AU>
<TI>Drugs for preventing malaria in pregnant women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-08-26 12:10:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-08-26 12:10:24 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD000169. DOI: 10.1002/14651858.CD000169.pub2."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-09-02 09:25:23 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Deeks JJ, Altman DG</AU>
<TO>Chapter 16: Special topics in statistics</TO>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)</SO>
<YR>2011</YR>
<ED>Higgins JPT, Deeks JJ, Altman DG</ED>
<PB>updated March 2011</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kapito_x002d_Tembo-2011" MODIFIED="2011-06-01 21:36:51 +0100" MODIFIED_BY="[Empty name]" NAME="Kapito-Tembo 2011" TYPE="JOURNAL_ARTICLE">
<AU>Kapito-Tembo A, Meshnick SR, van Hensbroek MB, Phiri K, Fitzgerald M, Mwapasa V</AU>
<TI>Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2011</YR>
<VL>203</VL>
<NO>4</NO>
<PG>464-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Korenromp-2005" NAME="Korenromp 2005" TYPE="UNPUBLISHED">
<AU>Korenromp E, for the RBM Monitoring and Evaluation Reference Group &amp; MERG Task Force on Malaria Morbidity</AU>
<TI>Malaria incidence estimates at country level for the year 2004 - Proposed estimates and draft report</TI>
<SO>www.who.int/malaria/docs/incidence_estimations2.pdf</SO>
<YR>2005 (accessed on 22 Septermber 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Korenromp-2005a" MODIFIED="2011-08-07 17:44:32 +0100" MODIFIED_BY="[Empty name]" NAME="Korenromp 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Korenromp EL, Williams BG, de Vlas SJ, Gouws E, Gilks CF, Ghys PD, et al</AU>
<TI>Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa</TI>
<SO>Emerging infectious diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>9</NO>
<PG>1410-9</PG>
<IDENTIFIERS MODIFIED="2011-08-07 17:44:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16229771"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kublin-2005" NAME="Kublin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kublin JG, Patnaik P, Jere CS, Miller WC, Hoffman IF, Chimbiya N, et al</AU>
<TI>Effects of plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<NO>9455</NO>
<PG>233-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2011-09-05 11:58:44 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J.</AU>
<TI>Chapter 6: Searching for studies.</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011)</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration. Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malamba-2007" MODIFIED="2011-09-02 09:09:50 +0100" MODIFIED_BY="[Empty name]" NAME="Malamba 2007" TYPE="JOURNAL_ARTICLE">
<AU>Malamba S, Hladik W, Reingold A, Banage F, McFarland W, Rutherford G, et al</AU>
<TI>The effect of HIV on morbidity and mortality in children with severe malarial anaemia</TI>
<SO>Malaria Journal</SO>
<YR>2007</YR>
<VL>6</VL>
<PG>143</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malenga-2009" MODIFIED="2011-09-02 09:20:44 +0100" MODIFIED_BY="[Empty name]" NAME="Malenga 2009" TYPE="JOURNAL_ARTICLE">
<AU>Malenga G, Wirima J, Kazembe P, Nyasulu Y, Mbvundula M, Nyirenda C, et al</AU>
<TI>Developing national treatment policy for falciparum malaria in Africa: Malawi experience</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2009</YR>
<VL>103</VL>
<NO>Suppl 1</NO>
<PG>S15-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Msamanga-2009" MODIFIED="2011-09-02 09:10:27 +0100" MODIFIED_BY="[Empty name]" NAME="Msamanga 2009" TYPE="JOURNAL_ARTICLE">
<AU>Msamanga GI, Taha TE, Young AM, Brown ER, Hoffman IF, Read JS, et al</AU>
<TI>Placental malaria and mother-to-child transmission of human immunodeficiency virus-1</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2009</YR>
<VL>80</VL>
<NO>4</NO>
<PG>508-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulenga-2006" MODIFIED="2011-09-02 09:20:26 +0100" MODIFIED_BY="[Empty name]" NAME="Mulenga 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mulenga M, Van Geertruyden JP, Mwananyanda L, Chalwe V, Moerman F, Chilengi R, et al</AU>
<TI>Safety and efficacy of lumefantrine-artemether (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults</TI>
<SO>Malaria Journal</SO>
<YR>2006</YR>
<VL>5</VL>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parise-1998" NAME="Parise 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, et al</AU>
<TI>Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>5</NO>
<PG>813-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perrault-2009" MODIFIED="2011-09-02 09:20:59 +0100" MODIFIED_BY="[Empty name]" NAME="Perrault 2009" TYPE="JOURNAL_ARTICLE">
<AU>Perrault SD, Hajek J, Zhong K, Owino SO, Sichangi M, Smith G, et al</AU>
<TI>Human immunodeficiency virus co-infection increases placental parasite density and transplacental malaria transmission in Western Kenya</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2009</YR>
<VL>80</VL>
<NO>1</NO>
<PG>119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-5.0" MODIFIED="2011-06-02 04:09:24 +0100" MODIFIED_BY="[Empty name]" NAME="Review Manager 5.0" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0 for Windows</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<MD>CD-ROM and Internet</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steketee-1996" MODIFIED="2010-11-12 08:50:15 +0000" MODIFIED_BY="[Empty name]" NAME="Steketee 1996" TYPE="JOURNAL_ARTICLE">
<AU>Steketee RW, Wirima JJ, Bloland PB, Chilima B, Mermin JH, Chitsulo L, et al</AU>
<TI>Impairment of a pregnant woman's acquired ability to limit plasmodium falciparum by infection with human immunodeficiency virus type-1</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1996</YR>
<VL>55 Suppl 1</VL>
<PG>42-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tagbor-2006" NAME="Tagbor 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tagbor H, Bruce J, Browne E, Randal A, Greenwood B, Chandramohan D</AU>
<TI>Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<NO>9544</NO>
<PG>1349-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ter-Kuile-2004" MODIFIED="2011-09-02 09:21:14 +0100" MODIFIED_BY="[Empty name]" NAME="ter Kuile 2004" TYPE="JOURNAL_ARTICLE">
<AU>ter Kuile FO, Parise ME, Verhoeff FH, Udhayakumar V, Newman RD, van Eijk AM, et al</AU>
<TI>The burden of co-infection with the human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2004</YR>
<VL>71</VL>
<NO>Suppl 2</NO>
<PG>41-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UNAIDS-2010" MODIFIED="2011-05-31 10:14:52 +0100" MODIFIED_BY="[Empty name]" NAME="UNAIDS 2010" TYPE="BOOK_SECTION">
<AU>United Nations Programme on HIV/AIDS</AU>
<TI>Epidemic update</TI>
<SO>UNAIDS Report on the global AIDS epidemic 2010</SO>
<YR>2010</YR>
<PG>16-61</PG>
<PB>UNAIDS</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Geertruyden-2006" NAME="Van Geertruyden 2006" TYPE="JOURNAL_ARTICLE">
<AU>Van Geertruyden JP, Mulenga M, Mwananyanda L, Chalwe V, Moerman F, Chilengi R, et al</AU>
<TI>HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2006</YR>
<VL>194</VL>
<NO>7</NO>
<PG>917-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitworth-2000" NAME="Whitworth 2000" TYPE="JOURNAL_ARTICLE">
<AU>Whitworth J, Morgan D, Quigley M, Smith A, Mayanja B, Eotu H, et al</AU>
<TI>Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<NO>9235</NO>
<PG>1051-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2004" NAME="WHO 2004" TYPE="BOOK">
<AU>World Health Organization, Regional Office for Africa</AU>
<SO>A strategic framework for malaria prevention and control during pregnancy in the African region [AFR/MAL/04/01]</SO>
<YR>2004</YR>
<PB>World Health Organization</PB>
<CY>Brazzaville</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2010" MODIFIED="2011-06-01 21:15:42 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2010" TYPE="BOOK">
<AU>World Health Organization</AU>
<TI>Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach</TI>
<SO>Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach</SO>
<YR>2010</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2010a" MODIFIED="2011-08-26 12:18:32 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2010a" TYPE="BOOK">
<AU>WHO/UNAIDS/UNICEF</AU>
<SO>Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector</SO>
<YR>2010</YR>
<PB>WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-07-18 15:33:03 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-07-18 15:33:03 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-07-18 15:33:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Filler-2006">
<CHAR_METHODS MODIFIED="2010-11-29 12:17:32 +0000" MODIFIED_BY="[Empty name]">
<P>Design: RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: 266 were enrolled</P>
<P>Inclusion Criteria: HIV positive women in the first or second pregnancy</P>
<P>Exclusion criteria: prior adverse reaction to sulfa-containing drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-18 15:33:03 +0100" MODIFIED_BY="[Empty name]">
<P>1. Monthly intermittent preventive treatment using sulphadoxine-pyrimethamine</P>
<P>2. Control: 2 doses of sulphadoxine-pyrimethamine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-02 09:07:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. Maternal anaemia<BR/>2. Peripheral parasitaemia<BR/>3. Placental parasitaemia<BR/>4. Maternal haemoglobin at delivery<BR/>5. Neonatal death<BR/>6. Birth weight<BR/>7. ADR</P>
<P>Not included in this review<BR/>Uncomplicated malaria<BR/>3rd trimester anaemia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: Malawi</P>
<P>Date: 2002-5</P>
<P>Funding: WHO/ CDC</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-18 15:32:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hamer-2007">
<CHAR_METHODS MODIFIED="2010-11-29 12:02:12 +0000" MODIFIED_BY="[Empty name]">
<P>Design: RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: 456 were enrolled</P>
<P>Inclusion Criteria: <BR/>HIV positive women of any gravidity</P>
<P>Exclusion criteria: <BR/>prior adverse reaction to sulfa-containing drugs and women aged &lt;18 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-18 15:32:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. Monthly intermittent preventive treatment using sulphadoxine-pyrimethamine</P>
<P>2. Control: 2 doses of sulphadoxine-pyrimethamine, one in 2nd trimester and the other in 3rd trimester</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-02 09:07:55 +0100" MODIFIED_BY="[Empty name]">
<P>1. Placental malaria (by histology)<BR/>2. Placental parasitaemia<BR/>3. Peripheral parasitaemia<BR/>4. Placental malaria<BR/>5. Maternal anaemia at delivery<BR/>6. LBW<BR/>7. ADR</P>
<P>Not included in this review<BR/>1. Gestational age<BR/>2. Uncomplicated malaria<BR/>3. Cord blood parasitaemia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: Zambia</P>
<P>Date: 2003 - 4 </P>
<P>Funding: Cooperative Agreement No. S1954-21/21</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>RCT = Randomized Controlled Trial<BR/>HIV = Human Immonodeficiency Virus<BR/>ADR = Adverse Drug Reactions<BR/>CDC = Centers for Disease Control<BR/>WHO = World Health Organization<BR/>LBW = Low Birth Weight</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-04-21 10:19:58 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-04-21 10:19:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parise-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-21 10:19:58 +0100" MODIFIED_BY="[Empty name]">
<P>Non-randomized trial with treatment assigned based day of clinic visit</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-09-02 09:08:04 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-11-11 20:55:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Korukiiko">
<CHAR_STUDY_NAME MODIFIED="2010-11-11 20:53:03 +0000" MODIFIED_BY="[Empty name]">
<P>"Influence of HIV infection on the effectiveness of malaria prevention during pregnancy, with emphasis on the effect of chloroquine on HIV viral load among pregnant women in Uganda"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Expected enrolment: sample size not given</P>
<P>Minimum age: 15</P>
<P>Inclusion criteria: HIV positive pregnant women 14-24 weeks gestation</P>
<P>Exclusion criteria: pregnant women with severe disease or at risk pregnancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-11 20:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>1: Intervention: sulphadoxine-pyrimethamine plus chloroquine</P>
<P>2. Control: sulfadoxine-pyrimethamine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Maternal parasitaemia;<BR/>2. Placental parasitaemia<BR/>3. Clinical malaria<BR/>4. Maternal and infant Hb<BR/>5. Birth weight<BR/>6. Congenital parasitaemia<BR/>7. Maternal HIV viral load</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Not clear</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Lucy N Korukiiko Uganda AIDS Commission<BR/>Kampala<BR/>P.O. Box 10779</P>
<P>lucymanzi@yahoo.co.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00132535</P>
<P>Data analysis on going.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-11-12 15:06:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Macarthur">
<CHAR_STUDY_NAME>
<P>"Efficacy of intermittent sulfadoxine-pyrimethamine and sulfadoxine-pyrimethamine + artesunate treatment in the prevention of malaria in pregnancy in an area with chloroquine-resistant plasmodium falciparum"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-11-12 15:06:04 +0000" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS>
<P>Expected enrolment: sample size not given</P>
<P>Minimum age: 15</P>
<P>Inclusion criteria: HIV (?) pregnant women aged 15 years or older in their 1st or 2nd pregnancy </P>
<P>Exclusion criteria: multigravida women, gestation age &lt; 16 weeks or &gt; 36 weeks, prior history of allergic reactions to sulfadoxine-pyrimethamine or artesunate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Intervention: sulfadoxine-pyrimethamine plus artesunate</P>
<P>2. Control: sulfadoxine-pyrimethamine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-11 20:55:49 +0000" MODIFIED_BY="[Empty name]">
<P>1. Placental<BR/>parasitaemia</P>
<P>2. Adverse reactions.</P>
<P>3. Parasitemia at delivery</P>
<P>4. Maternal illness<BR/>5. Birth weight<BR/>6. Gestational age</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>January 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-11-11 20:56:03 +0000" MODIFIED_BY="[Empty name]">
<P>John Macarthur<BR/>Tel: 770-488-7755<BR/>ZAE5@CDC.GOV</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00164255</P>
<P>Study finished and data analysis going on</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-09-02 09:07:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manyando">
<CHAR_STUDY_NAME MODIFIED="2010-11-12 14:56:38 +0000" MODIFIED_BY="[Empty name]">
<P>Establishing Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-11-12 15:06:23 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-12 15:16:59 +0000" MODIFIED_BY="[Empty name]">
<P>Expected enrolment: sample size not given.</P>
<P>Minimum age: All HIV pregnant women, no age limit given.</P>
<P>Inclusion criteria: HIV positive and HIV negative pregnant women, Hb &gt; 7 g/dl, gestational age between 16 and 28 weeks.</P>
<P>Exclusion criteria: Severe anaemia (Hb&lt;7 g/dl) and HIV women already on cotrimoxazole</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-02 09:07:59 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Intervention: co-trimoxazole prophylaxis</LI>
<LI>Control: sulfadoxine-pyrimethamine</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-12 15:20:49 +0000" MODIFIED_BY="[Empty name]">
<P>1. Placental parasitaemia</P>
<P>2. Adverse reactions.</P>
<P>3. Parasitemia at delivery</P>
<P>4. Maternal illness<BR/>5. Birth weight<BR/>6. Gestational age</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-11-12 14:59:12 +0000" MODIFIED_BY="[Empty name]">
<P>April 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-11-12 14:58:02 +0000" MODIFIED_BY="[Empty name]">
<P>Christine Manyando, MD<BR/>Tel: 260 212 621732<BR/>
<A HREF="mailto:cmanyando@yahoo.com">cmanyando@yahoo.com</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-11-12 14:58:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<A HREF="http://clinicaltrials.gov/show/NCT01053325">NCT01053325</A>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>AIDS = Acquired Immunodeficiency syndrome<BR/>Hb = haemoglobin<BR/>HIV = Human Immunodeficiency Virus<BR/>IPTp = Intermittent Preventive Treatment in pregnancy<BR/>MTCT = mother-to-child HIV transmission</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-09-02 09:07:53 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-11-29 12:09:59 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-29 12:09:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Filler-2006">
<DESCRIPTION>
<P>Generation of allocation sequence: permuted blocks of random length.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-29 12:00:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hamer-2007">
<DESCRIPTION>
<P>Generation of allocation sequence: randomization was done in blocks of 20</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-11-29 12:09:57 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-29 12:09:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Filler-2006">
<DESCRIPTION>
<P>No details of allocation concealment are given by the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-29 12:01:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hamer-2007">
<DESCRIPTION>
<P>Allocation concealment: participants were assigned sequential ID numbers corresponding to a sealed package of trial drugs whilst randomization codes were retained in the USA </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-11-29 13:10:44 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Patients</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Clinicians</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Technicians</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-29 13:10:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Filler-2006">
<DESCRIPTION>
<P>No. "Neither study participants nor clinicians were blinded to group assignment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-29 13:10:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Filler-2006">
<DESCRIPTION>
<P>No. "Neither study participants nor clinicians were blinded to group assignment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-29 13:10:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Filler-2006">
<DESCRIPTION>
<P>Blinding was only done for the laboratory technicians assessing the outcome of placental malaria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-29 13:08:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hamer-2007">
<DESCRIPTION>
<P>Investigators were blinded. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-29 13:08:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hamer-2007">
<DESCRIPTION>
<P>Trial participants were blinded. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-29 13:08:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hamer-2007">
<DESCRIPTION>
<P>Laboratory/ pathologists were all blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-09-02 09:07:53 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-09-02 09:07:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Filler-2006">
<DESCRIPTION>
<P>The proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate as demonstrated by the sensitivity analysis .</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-30 07:32:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hamer-2007">
<DESCRIPTION>
<P>Inclusion of randomized participants in the analysis: participants with data available were analyzed and not everyone randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-11-29 12:22:37 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-29 12:22:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Filler-2006">
<DESCRIPTION>
<P>The method section does not set out clearly the outcomes which were to be measured.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-29 12:07:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hamer-2007">
<DESCRIPTION>
<P>All outcomes are included in the results section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-11-30 06:12:07 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 06:12:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Filler-2006">
<DESCRIPTION>
<P>No other biases suspected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 06:11:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hamer-2007">
<DESCRIPTION>
<P>No other biases suspected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-07-18 15:39:16 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-07-18 15:39:05 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-02-03 09:52:27 +0000" MODIFIED_BY="[Empty name]">Primigravidae and secundigravidae</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Monthly SP during pregnancy compared to two-doses for HIV +ve women in their first or second pregnancy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> HIV-positive pregnant women living<BR/>
<B>Settings: </B>Malaria endemic areas<BR/>
<B>Intervention:</B> Monthly sulfadoxine-pyrimethamine (SP) compared to standard 2-dose SP<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Standard regimen </B>
<BR/>(2 doses)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Monthly regimen </B>
<BR/>(3 or more doses)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Maternal parasitaemia </B>
<BR/>(at delivery)</P>
</TD>
<TD>
<P>
<B>22 per 100</B>
</P>
</TD>
<TD>
<P>
<B>5 per 100</B>
<BR/>(3 to 10)</P>
</TD>
<TD>
<P>
<B>RR 0.25 </B>
<BR/>(0.14 to 0.43)</P>
</TD>
<TD>
<P>463<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Placental parasitaemia</B>
<BR/>(at delivery)</P>
</TD>
<TD>
<P>
<B>14 per 100</B>
</P>
</TD>
<TD>
<P>
<B>5 per 100</B>
<BR/>(3 to 10)</P>
</TD>
<TD>
<P>
<B>RR 0.38 </B>
<BR/>(0.21 to 0.7)</P>
</TD>
<TD>
<P>459<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Maternal anaemia </B>
<BR/>(Hb &lt; 11 g/dL at delivery)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>66 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>61 per 100</B>
<BR/>(47 to 79)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.93 </B>
<BR/>(0.72 to 1.2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>447<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Low birth weight</B>
<BR/>(&lt; 2.5 kg)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>16 per 100</B>
<BR/>(11 to 25)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.8 </B>
<BR/>(0.52 to 1.23)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>469<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Neonatal mortality</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>8 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>2 per 100</B>
<BR/>(1 to 8)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.29 </B>
<BR/>(0.08 to 1.05)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>253<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (eg the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded by 1 under risk of bias: Both studies had a high proportion of missing outcomes which sensitivity analysis indicates could induce clinically relevant bias.<BR/>
<SUP>2</SUP> Downgraded by 1 for imprecision: Larger trials would be necessary to have full confidence in this result.<BR/>
<SUP>3</SUP> Downgraded by 2 for imprecision: The number of neonatal deaths was very low, and the single trial underpowered to detect an effect on mortality. In addition, one study which did not separate women into primigravidae, secundigravidae and multigravidae found a trend towards higher neonatal mortality with monthly SP.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2012-07-18 15:39:16 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2012-02-03 09:52:45 +0000" MODIFIED_BY="[Empty name]">Multigravidae (greater than 2 pregnancies)</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Multigravidae (greater than 2 pregnancies)</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> HIV-positive pregnant women<BR/>
<B>Settings: </B>Malaria endemic areas<BR/>
<B>Intervention:</B> Monthly sulfadoxine-pyrimethamine (SP) compared to standard 2-dose SP<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Standard regimen</B>
<BR/>(2 doses)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Monthly regimen </B>
</P>
<P>(3 or more doses)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Maternal parasitaemia </B>
<BR/>(at delivery)</P>
</TD>
<TD>
<P>
<B>1 per 100</B>
</P>
</TD>
<TD>
<P>
<B>1 per 100</B>
<BR/>(0 to 19)</P>
</TD>
<TD>
<P>
<B>RR 0.94 </B>
<BR/>(0.06 to 14.75)</P>
</TD>
<TD>
<P>159<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Placental parasitaemia</B>
<BR/>(at delivery)</P>
</TD>
<TD>
<P>
<B>1 per 100</B>
</P>
</TD>
<TD>
<P>
<B>3 per 100</B>
<BR/>(0 to 27)</P>
</TD>
<TD>
<P>
<B>RR 1.87 </B>
<BR/>(0.17 to 20.23)</P>
</TD>
<TD>
<P>153<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Maternal anaemia </B>
<BR/>(Hb &lt; 11 g/dL at delivery)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>44 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>43 per 100</B>
<BR/>(31 to 62)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.69 to 1.4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>157<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Low birth weight</B>
<BR/>(&lt; 2.5 kg)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>9 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>13 per 100</B>
<BR/>(5 to 32)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.41 </B>
<BR/>(0.57 to 3.51)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>155<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Neonatal mortality</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (eg the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded by 1 under risk of bias: Both studies had a high proportion of missing outcomes which sensitivity analysis indicates could induce clinically relevant bias.<BR/>
<SUP>2</SUP> Downgraded by 1 for imprecision: This single trial is too small to have any confidence in this result.<BR/>
<SUP>3 </SUP>Downgraded by 1 for indirectness: This trial was conducted in a low malaria transmission setting and maternal and placental parasitaemia were rare in both groups.<BR/>
<SUP>4 </SUP>This trial did not report neonatal mortality separately for mutigravid women.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-08-02 10:42:24 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-08-02 10:42:24 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Detailed search strategies</TITLE>
<TABLE COLS="6" ROWS="19">
<TR>
<TH>
<P>Search set</P>
</TH>
<TH>
<P>CIDG SR^</P>
</TH>
<TH>
<P>CENTRAL</P>
</TH>
<TH>
<P>MEDLINE^^</P>
</TH>
<TH>
<P>EMBASE^^</P>
</TH>
<TH>
<P>LILACS^^</P>
</TH>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>malaria</P>
</TD>
<TD>
<P>malaria</P>
</TD>
<TD>
<P>malaria</P>
</TD>
<TD>
<P>malaria</P>
</TD>
<TD>
<P>malaria</P>
</TD>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>prevent*</P>
</TD>
<TD>
<P>prevent*</P>
</TD>
<TD>
<P>prevent*</P>
</TD>
<TD>
<P>prevent*</P>
</TD>
<TD>
<P>prevent*</P>
</TD>
</TR>
<TR>
<TD>
<P>3</P>
</TD>
<TD>
<P>prophyla*</P>
</TD>
<TD>
<P>prophyla*</P>
</TD>
<TD>
<P>prophyla*</P>
</TD>
<TD>
<P>prophyla*</P>
</TD>
<TD>
<P>prophyla*</P>
</TD>
</TR>
<TR>
<TD>
<P>4</P>
</TD>
<TD>
<P>chemoprophyla*</P>
</TD>
<TD>
<P>chemoprophyla*</P>
</TD>
<TD>
<P>chemoprophyla*</P>
</TD>
<TD>
<P>chemoprophyla*</P>
</TD>
<TD>
<P>chemoprophyla*</P>
</TD>
</TR>
<TR>
<TD>
<P>5</P>
</TD>
<TD>
<P>intermittent presumptive treatment</P>
</TD>
<TD>
<P>intermittent presumptive treatment</P>
</TD>
<TD>
<P>intermittent presumptive treatment</P>
</TD>
<TD>
<P>intermittent presumptive treatment</P>
</TD>
<TD>
<P>intermittent presumptive treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>6</P>
</TD>
<TD>
<P>intermittent presumptive therapy</P>
</TD>
<TD>
<P>intermittent presumptive therapy</P>
</TD>
<TD>
<P>intermittent presumptive therapy</P>
</TD>
<TD>
<P>intermittent presumptive therapy</P>
</TD>
<TD>
<P>intermittent presumptive therapy</P>
</TD>
</TR>
<TR>
<TD>
<P>7</P>
</TD>
<TD>
<P>intermittent preventive treatment</P>
</TD>
<TD>
<P>intermittent preventive treatment</P>
</TD>
<TD>
<P>intermittent preventive treatment</P>
</TD>
<TD>
<P>intermittent preventive treatment</P>
</TD>
<TD>
<P>intermittent preventive treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>8</P>
</TD>
<TD>
<P>intermittent preventive therapy</P>
</TD>
<TD>
<P>intermittent preventive therapy</P>
</TD>
<TD>
<P>intermittent preventive therapy</P>
</TD>
<TD>
<P>intermittent preventive therapy</P>
</TD>
<TD>
<P>intermittent preventive therapy</P>
</TD>
</TR>
<TR>
<TD>
<P>9</P>
</TD>
<TD>
<P>2-8/or</P>
</TD>
<TD>
<P>2-8/or</P>
</TD>
<TD>
<P>2-8/or</P>
</TD>
<TD>
<P>2-8/or</P>
</TD>
<TD>
<P>2-8/or</P>
</TD>
</TR>
<TR>
<TD>
<P>10</P>
</TD>
<TD>
<P>1 and 9</P>
</TD>
<TD>
<P>1 and 9</P>
</TD>
<TD>
<P>1 and 9</P>
</TD>
<TD>
<P>1 and 9</P>
</TD>
<TD>
<P>1 and 9</P>
</TD>
</TR>
<TR>
<TD>
<P>11</P>
</TD>
<TD>
<P>HIV</P>
</TD>
<TD>
<P>HIV INFECTIONS</P>
</TD>
<TD>
<P>HIV INFECTIONS</P>
</TD>
<TD>
<P>HUMAN-IMMUNODEFICIENCY-VIRUS-INFECTION</P>
</TD>
<TD>
<P>HIV</P>
</TD>
</TR>
<TR>
<TD>
<P>12</P>
</TD>
<TD>
<P>AIDS</P>
</TD>
<TD>
<P>10 and 11</P>
</TD>
<TD>
<P>10 and 11</P>
</TD>
<TD>
<P>ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME</P>
</TD>
<TD>
<P>AIDS</P>
</TD>
</TR>
<TR>
<TD>
<P>13</P>
</TD>
<TD>
<P>7 or 8</P>
</TD>
<TD>
<P>pregnan*</P>
</TD>
<TD>
<P>pregnan*</P>
</TD>
<TD>
<P>HUMAN-IMMUNODEFICIENCY-VIRUS-INFECTED-PATIENT</P>
</TD>
<TD>
<P>11 or 12</P>
</TD>
</TR>
<TR>
<TD>
<P>14</P>
</TD>
<TD>
<P>10 and 13</P>
</TD>
<TD>
<P>12 and 13</P>
</TD>
<TD>
<P>12 and 13</P>
</TD>
<TD>
<P>11 or 12 or 13</P>
</TD>
<TD>
<P>10 and 13</P>
</TD>
</TR>
<TR>
<TD>
<P>15</P>
</TD>
<TD>
<P>pregnan*</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>10 and 14</P>
</TD>
<TD>
<P>pregnan*</P>
</TD>
</TR>
<TR>
<TD>
<P>16</P>
</TD>
<TD>
<P>14 and 15</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>pregnan*</P>
</TD>
<TD>
<P>14 and 15</P>
</TD>
</TR>
<TR>
<TD>
<P>17</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>15 and 16</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>^Cochrane Infectious Diseases Group Specialized Register</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>^^Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>); upper case: MeSH or EMTREE heading; lower case: free text term</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2011-09-02 09:08:18 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Trial outcomes</TITLE>
<TABLE COLS="3" ROWS="13">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Trial1 - Filler 2006</P>
</TH>
<TH>
<P>Trial 2 - Hamer 2007</P>
</TH>
</TR>
<TR>
<TD>
<P>Uncomplicated malaria</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Placental malaria (based on histology)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Placental parasitaemia</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Peripheral parasitaemia</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Cord blood parasitaemia</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Low birth weight</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Birth weight</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Maternal anaemia ( in 3rd trimester or at delivery)</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Maternal haemoglobin (in 3rd trimester or at delivery)</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Pre-term delivery</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Neonatal death</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse Drug Reactions</P>
</TD>
<TD>
<P>x</P>
</TD>
<TD>
<P>x</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2011-09-02 09:08:20 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-04-21 14:43:21 +0100" MODIFIED_BY="[Empty name]">Reported Adverse Drug Reactions (ADRs)</TITLE>
<TABLE COLS="3" ROWS="3">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>ADRs: Mother</P>
</TH>
<TH>
<P>ADRs: Infant</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Filler-2006" TYPE="STUDY">Filler 2006</LINK>
</P>
</TD>
<TD>
<P>1. Less than 1% reported ADRs. 2. In no case was SP withheld because of ADR concerns. 3. No significant difference in proportion of women with ADRs in the 2-dose and monthly SP arms. 4. No severe ADRs reported</P>
</TD>
<TD>
<P>1. Neonatal jaundice observed in 0.4% of newborns.<BR/>2. One neonatal death with jaundice probably due to prematurity</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hamer-2007" TYPE="STUDY">Hamer 2007</LINK>
</P>
</TD>
<TD>
<P>1. Rates of ADRs were very low in both groups. 2. Rates did not differ between groups (RR 1.13 for ADRs in the monthly SP group relative to 2-dose, 95% CI 0.56-2.18). 3. One mother on monthly SP died from Stevens-Johnson syndrome</P>
</TD>
<TD>
<P>1. Rates of ADRs very low.<BR/>2. Rates similar across the treatment arms (RR 1.49 for ADRs in the monthly group relative to 2-dose SP, 95% CI 0.79-2.8)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-09-02 09:24:54 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-09-02 09:23:25 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Monthly sulfadoxine pyrimethamine (SP) compared to standard 2-dose SP</NAME>
<DICH_OUTCOME CHI2="2.441136630899753" CI_END="1.1155195589690554" CI_START="0.8350468195559971" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9651482061681607" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="183" I2="18.070952085019474" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.04747718939158595" LOG_CI_START="-0.07828917373223793" LOG_EFFECT_SIZE="-0.015405992170325981" METHOD="MH" MODIFIED="2011-09-02 09:22:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.29506250436668635" P_Q="0.7977273580332512" P_Z="0.6311000453328409" Q="0.06568427477798101" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.003777033838910415" TOTALS="YES" TOTAL_1="299" TOTAL_2="305" WEIGHT="100.00000000000001" Z="0.48017910433199273">
<NAME>Maternal anaemia: (haemoglobin less than 11g/dl)</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.560223816035726" CI_END="1.2017084672957596" CI_START="0.7185412084758314" DF="1" EFFECT_SIZE="0.9292346605278637" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="148" I2="60.94091486312281" ID="CMP-001.01.01" LOG_CI_END="0.07979912124298474" LOG_CI_START="-0.1435483199438623" LOG_EFFECT_SIZE="-0.031874599350438786" MODIFIED="2011-06-24 11:06:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10958341948488015" P_Z="0.5758717329179196" STUDIES="2" TAU2="0.022604101983443797" TOTAL_1="221" TOTAL_2="226" WEIGHT="84.95753059401535" Z="0.5594249606490039">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="1.16191006889174" CI_START="0.8921808727564007" EFFECT_SIZE="1.0181522181522182" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="91" LOG_CI_END="0.06517251523545887" LOG_CI_START="-0.04954709172586694" LOG_EFFECT_SIZE="0.007812711754795946" MODIFIED="2011-06-24 11:06:18 +0100" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.06738686500029575" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="118" VAR="0.004540989574568085" WEIGHT="65.61211994275304"/>
<DICH_DATA CI_END="1.0774788869165266" CI_START="0.5838444144214566" EFFECT_SIZE="0.7931456548347613" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="57" LOG_CI_END="0.032408768962250825" LOG_CI_START="-0.23370287028589512" LOG_EFFECT_SIZE="-0.10064705066182217" MODIFIED="2011-06-24 11:06:41 +0100" MODIFIED_BY="[Empty name]" ORDER="458" O_E="0.0" SE="0.15631529416821996" STUDY_ID="STD-Hamer-2007" TOTAL_1="86" TOTAL_2="108" VAR="0.024434471190897138" WEIGHT="19.345410651262313"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.032789243304583E-31" CI_END="1.400897670701987" CI_START="0.6910035990964717" DF="0" EFFECT_SIZE="0.9838827838827838" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" I2="100.0" ID="CMP-001.01.02" LOG_CI_END="0.14640641317832678" LOG_CI_START="-0.1605196905944458" LOG_EFFECT_SIZE="-0.007056638708059509" MODIFIED="2011-06-24 11:07:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.9281883998757384" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="79" WEIGHT="15.042469405984662" Z="0.09012434947499452">
<NAME>Multigravidae (greater than 2 pregnancies)</NAME>
<DICH_DATA CI_END="1.400897670701987" CI_START="0.6910035990964717" EFFECT_SIZE="0.9838827838827838" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.14640641317832678" LOG_CI_START="-0.1605196905944458" LOG_EFFECT_SIZE="-0.007056638708059509" MODIFIED="2011-06-24 11:07:12 +0100" MODIFIED_BY="[Empty name]" ORDER="459" O_E="0.0" SE="0.18028991266484337" STUDY_ID="STD-Hamer-2007" TOTAL_1="78" TOTAL_2="79" VAR="0.032504452608696846" WEIGHT="15.042469405984662"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.364830497441413" CI_END="1.317996541854214" CI_START="0.5910350815742826" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8825996791464564" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="54" I2="15.427342375537483" I2_Q="17.10435525835989" ID="CMP-001.02" LOG_CI_END="0.11991427076208612" LOG_CI_START="-0.2283867402998764" LOG_EFFECT_SIZE="-0.05423623476889514" METHOD="MH" MODIFIED="2011-09-02 09:22:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3065375333040673" P_Q="0.27205905140994513" P_Z="0.5415983993564429" Q="1.2063359940280196" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.021078537799242254" TOTALS="YES" TOTAL_1="314" TOTAL_2="310" WEIGHT="100.0" Z="0.6103976929609466">
<NAME>Low Birth Weight: birth weight less than 2.5 kg</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.174488676436291" CI_END="1.2300059175654778" CI_START="0.5220748458737409" DF="1" EFFECT_SIZE="0.8013458366003944" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="47" I2="14.856565238733141" ID="CMP-001.02.01" LOG_CI_END="0.08990720083765098" LOG_CI_START="-0.2822672310593465" LOG_EFFECT_SIZE="-0.09618001511084778" MODIFIED="2011-08-08 16:07:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2784809080787385" P_Z="0.31105243364335233" STUDIES="2" TAU2="0.015549151558673266" TOTAL_1="236" TOTAL_2="233" WEIGHT="82.421819183134" Z="1.0130162068841497">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="1.510942795067184" CI_START="0.5864322183970871" EFFECT_SIZE="0.9413105413105413" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="26" LOG_CI_END="0.17924802207764098" LOG_CI_START="-0.23178217771259998" LOG_EFFECT_SIZE="-0.026267077817479497" MODIFIED="2011-06-24 11:08:13 +0100" MODIFIED_BY="[Empty name]" ORDER="460" O_E="0.0" SE="0.24144117398909062" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="118" VAR="0.05829384049723033" WEIGHT="52.7369829827304"/>
<DICH_DATA CI_END="1.1757921195094307" CI_START="0.30253050260635544" EFFECT_SIZE="0.5964167845355964" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" LOG_CI_END="0.0703305450986506" LOG_CI_START="-0.5192308311081009" LOG_EFFECT_SIZE="-0.2244501430047251" MODIFIED="2011-06-24 11:08:20 +0100" MODIFIED_BY="[Empty name]" ORDER="461" O_E="0.0" SE="0.346311270759725" STUDY_ID="STD-Hamer-2007" TOTAL_1="101" TOTAL_2="115" VAR="0.11993149625521557" WEIGHT="29.684836200403602"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5144780034040677" CI_START="0.5658943207904429" DF="0" EFFECT_SIZE="1.4102564102564104" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.5458608294764797" LOG_CI_START="-0.2472646645409904" LOG_EFFECT_SIZE="0.14929808246774467" MODIFIED="2011-06-24 11:08:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.46058255979490437" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="77" WEIGHT="17.578180816866002" Z="0.7378879302327028">
<NAME>Multigravidae</NAME>
<DICH_DATA CI_END="3.5144780034040686" CI_START="0.5658943207904428" EFFECT_SIZE="1.4102564102564104" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5458608294764798" LOG_CI_START="-0.24726466454099047" LOG_EFFECT_SIZE="0.14929808246774467" MODIFIED="2011-06-24 11:08:41 +0100" MODIFIED_BY="[Empty name]" ORDER="462" O_E="0.0" SE="0.46588584122037563" STUDY_ID="STD-Hamer-2007" TOTAL_1="78" TOTAL_2="77" VAR="0.21704961704961703" WEIGHT="17.578180816866002"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.829827233897871" CI_END="8.232372506348963" CI_START="0.09802602481357581" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8983244133284828" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="82.84683302130392" I2_Q="82.84661149093515" ID="CMP-001.03" LOG_CI_END="0.9155250135755186" LOG_CI_START="-1.0086586086701483" LOG_EFFECT_SIZE="-0.046566797547314874" METHOD="MH" MODIFIED="2011-06-25 06:26:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.015756706003245302" P_Q="0.01575738036961427" P_Z="0.9244217215363667" Q="5.829751943597275" RANDOM="YES" SCALE="46.83" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.1168028758413264" TOTALS="YES" TOTAL_1="324" TOTAL_2="316" WEIGHT="100.0" Z="0.09486542241907993">
<NAME>Neonatal mortality</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0511467908049028" CI_START="0.08075893804237079" DF="0" EFFECT_SIZE="0.2913580246913581" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.021663368725709304" LOG_CI_START="-1.0928094005427955" LOG_EFFECT_SIZE="-0.5355730159085431" MODIFIED="2011-06-24 11:09:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05959642392771201" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="118" WEIGHT="50.19010522264689" Z="1.8837675557765767">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="1.0511467908049026" CI_START="0.08075893804237079" EFFECT_SIZE="0.291358024691358" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.02166336872570921" LOG_CI_START="-1.0928094005427955" LOG_EFFECT_SIZE="-0.5355730159085432" MODIFIED="2011-06-24 11:09:25 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.6546468213975002" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="118" VAR="0.4285624607658506" WEIGHT="50.19010522264689"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.372894563175308" CI_START="0.7523921803439821" DF="0" EFFECT_SIZE="2.7936507936507935" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="1.0158999634673382" LOG_CI_START="-0.12355572674620215" LOG_EFFECT_SIZE="0.4461721183605681" MODIFIED="2011-06-24 11:09:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.12480580048538552" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="198" WEIGHT="49.80989477735311" Z="1.5349105549313162">
<NAME>Primigravidae, secundigravidae and multigravidae women</NAME>
<DICH_DATA CI_END="10.372894563175308" CI_START="0.7523921803439821" EFFECT_SIZE="2.7936507936507935" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0158999634673382" LOG_CI_START="-0.12355572674620215" LOG_EFFECT_SIZE="0.4461721183605681" MODIFIED="2011-06-24 11:09:42 +0100" MODIFIED_BY="[Empty name]" ORDER="464" O_E="0.0" SE="0.6693219128280674" STUDY_ID="STD-Hamer-2007" TOTAL_1="189" TOTAL_2="198" VAR="0.447991822991823" WEIGHT="49.80989477735311"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6328939839130685" CI_END="0.7571285439971291" CI_START="0.23191617017298954" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41903502509034496" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="33" I2="0.0" I2_Q="38.34551302302221" ID="CMP-001.04" LOG_CI_END="-0.12083038046115653" LOG_CI_START="-0.6346689694643332" LOG_EFFECT_SIZE="-0.37774967496274486" METHOD="MH" MODIFIED="2011-09-02 09:23:25 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4419995086346338" P_Q="0.20282127825126217" P_Z="0.003954803018321659" Q="1.6219419689168881" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="306" TOTAL_2="306" WEIGHT="100.0" Z="2.8817444775215773">
<NAME>Placental parasitaemia: presence of malaria in the placental blood</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.00933724356458415" CI_END="0.6992736238801276" CI_START="0.20613474230992557" DF="1" EFFECT_SIZE="0.3796637831854099" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="32" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.15535285273981136" LOG_CI_START="-0.6858488053003325" LOG_EFFECT_SIZE="-0.4206008290200719" MODIFIED="2011-06-24 11:10:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9230206977452733" P_Z="0.001884259189897213" STUDIES="2" TAU2="0.0" TOTAL_1="227" TOTAL_2="232" WEIGHT="93.81867244899463" Z="3.1078935579738793">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="0.7476380929676658" CI_START="0.19783831732004706" EFFECT_SIZE="0.3845925925925926" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="25" LOG_CI_END="-0.12630857895693862" LOG_CI_START="-0.7036895904484479" LOG_EFFECT_SIZE="-0.4149990847026933" MODIFIED="2011-06-24 11:10:07 +0100" MODIFIED_BY="[Empty name]" ORDER="465" O_E="0.0" SE="0.339156464232214" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="118" VAR="0.11502710723049707" WEIGHT="79.20059401577583"/>
<DICH_DATA CI_END="1.663495377038152" CI_START="0.0753488036168605" EFFECT_SIZE="0.35403726708074534" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.22102159827390627" LOG_CI_START="-1.122923638992623" LOG_EFFECT_SIZE="-0.4509510203593583" MODIFIED="2011-06-24 11:10:40 +0100" MODIFIED_BY="[Empty name]" ORDER="466" O_E="0.0" SE="0.789440085006576" STUDY_ID="STD-Hamer-2007" TOTAL_1="92" TOTAL_2="114" VAR="0.62321564781519" WEIGHT="14.6180784332188"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.23040637368147" CI_START="0.1734860830016392" DF="0" EFFECT_SIZE="1.8734177215189873" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="1.3060046066499387" LOG_CI_START="-0.7607353584409068" LOG_EFFECT_SIZE="0.27263462410451594" MODIFIED="2011-06-24 11:10:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6050874187663173" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="74" WEIGHT="6.181327551005366" Z="0.5170984770306882">
<NAME>Multigravidae (greater than 2 pregnancies)</NAME>
<DICH_DATA CI_END="20.23040637368147" CI_START="0.1734860830016392" EFFECT_SIZE="1.8734177215189873" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3060046066499387" LOG_CI_START="-0.7607353584409068" LOG_EFFECT_SIZE="0.27263462410451594" MODIFIED="2011-06-24 11:10:54 +0100" MODIFIED_BY="[Empty name]" ORDER="467" O_E="0.0" SE="1.2140132860221857" STUDY_ID="STD-Hamer-2007" TOTAL_1="79" TOTAL_2="74" VAR="1.473828258638385" WEIGHT="6.181327551005366"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8515813224555415" CI_END="0.4521300796757624" CI_START="0.15341221935766883" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2633671941632411" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.34473659890986863" LOG_CI_START="-0.8141400472432453" LOG_EFFECT_SIZE="-0.579438323076557" METHOD="MH" MODIFIED="2011-09-02 09:23:08 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6532530973740063" P_Q="0.35622311908434123" P_Z="1.3061549532006213E-6" Q="0.8511647716159008" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="315" TOTAL_2="307" WEIGHT="100.0" Z="4.83881508976799">
<NAME>Maternal peripheral parasitaemia</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.157422012508047E-4" CI_END="0.43431963198090695" CI_START="0.1442450304272215" DF="1" EFFECT_SIZE="0.2502967209737786" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="51" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-0.3621905393500029" LOG_CI_START="-0.8408991403574175" LOG_EFFECT_SIZE="-0.6015448398537102" MODIFIED="2011-06-24 11:11:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.983732454860628" P_Z="8.402522136632894E-7" STUDIES="2" TAU2="0.0" TOTAL_1="233" TOTAL_2="230" WEIGHT="96.15017748537883" Z="4.92577830737963">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="0.4514640760751323" CI_START="0.13814564249889094" EFFECT_SIZE="0.24973544973544973" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="42" LOG_CI_END="-0.34537680168058854" LOG_CI_START="-0.8596628093977243" LOG_EFFECT_SIZE="-0.6025198055391564" MODIFIED="2011-06-24 11:11:17 +0100" MODIFIED_BY="[Empty name]" ORDER="468" O_E="0.0" SE="0.3020941466898412" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="118" VAR="0.09126087346426329" WEIGHT="83.30731441188803"/>
<DICH_DATA CI_END="1.1473477309749915" CI_START="0.05621650026611631" EFFECT_SIZE="0.25396825396825395" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="0.05969506110664858" LOG_CI_START="-1.2501361947019622" LOG_EFFECT_SIZE="-0.595220566797657" MODIFIED="2011-06-24 11:11:28 +0100" MODIFIED_BY="[Empty name]" ORDER="469" O_E="0.0" SE="0.7694013634312632" STUDY_ID="STD-Hamer-2007" TOTAL_1="98" TOTAL_2="112" VAR="0.5919784580498867" WEIGHT="12.842863073490797"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.75214561487229" CI_START="0.059772105596896" DF="0" EFFECT_SIZE="0.9390243902439024" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="1.168855190546824" LOG_CI_START="-1.2235014449692936" LOG_EFFECT_SIZE="-0.027323127211234845" MODIFIED="2011-06-24 11:11:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.964291009469734" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="77" WEIGHT="3.8498225146211733" Z="0.04476953350851342">
<NAME>Multigravidae (greater than 2 pregnancies)</NAME>
<DICH_DATA CI_END="14.752145614872298" CI_START="0.059772105596895976" EFFECT_SIZE="0.9390243902439024" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1688551905468243" LOG_CI_START="-1.2235014449692938" LOG_EFFECT_SIZE="-0.027323127211234845" MODIFIED="2011-06-24 11:11:38 +0100" MODIFIED_BY="[Empty name]" ORDER="470" O_E="0.0" SE="1.4052821300585046" STUDY_ID="STD-Hamer-2007" TOTAL_1="82" TOTAL_2="77" VAR="1.9748178650617676" WEIGHT="3.8498225146211733"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="121.01850699690658" CI_END="0.10645831609151875" CI_START="0.08605144060140553" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09625487834646214" ESTIMABLE="YES" I2="98.34736020991308" I2_Q="99.17286951203167" ID="CMP-001.06" MODIFIED="2011-06-25 17:22:01 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.1102230246251565E-16" P_Q="6.661338147750939E-16" P_Z="2.5103721636074776E-76" Q="120.89990812166596" RANDOM="NO" SCALE="0.25" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="318" UNITS="" WEIGHT="100.0" Z="18.489464003124898">
<NAME>Birth weight in kilograms</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2-dose SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Monthly SP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.11859887524064888" CI_END="0.14601000281473303" CI_START="0.12160376031860291" DF="1" EFFECT_SIZE="0.13380688156666798" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" MODIFIED="2011-06-25 15:09:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7305591732909801" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="237" TOTAL_2="237" WEIGHT="69.91191290990898" Z="21.490950013781866">
<NAME>Primigravidae and secundigravidae</NAME>
<CONT_DATA CI_END="0.24603939205145856" CI_START="-0.026039392051458804" EFFECT_SIZE="0.10999999999999988" ESTIMABLE="YES" MEAN_1="2.85" MEAN_2="2.74" MODIFIED="2011-06-24 11:13:10 +0100" MODIFIED_BY="[Empty name]" ORDER="471" SD_1="0.54" SD_2="0.56" SE="0.06940912849650302" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="118" WEIGHT="0.5625532955166702"/>
<CONT_DATA CI_END="0.146252516372109" CI_START="0.1217474836278908" EFFECT_SIZE="0.1339999999999999" ESTIMABLE="YES" MEAN_1="2.96" MEAN_2="2.826" MODIFIED="2011-06-25 15:09:58 +0100" MODIFIED_BY="[Empty name]" ORDER="472" SD_1="0.04815" SD_2="0.04411" SE="0.006251398734239705" STUDY_ID="STD-Hamer-2007" TOTAL_1="102" TOTAL_2="119" WEIGHT="69.34935961439231"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.02760155412789995" CI_START="-0.009601554127900157" DF="0" EFFECT_SIZE="0.008999999999999897" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" MODIFIED="2011-06-25 15:10:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.34298163035153006" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="81" WEIGHT="30.08808709009102" Z="0.948290435281584">
<NAME>Multigravidae (greater than 2 pregnancies)</NAME>
<CONT_DATA CI_END="0.02760155412789995" CI_START="-0.009601554127900157" EFFECT_SIZE="0.008999999999999897" ESTIMABLE="YES" MEAN_1="3.021" MEAN_2="3.012" MODIFIED="2011-06-25 15:10:34 +0100" MODIFIED_BY="[Empty name]" ORDER="473" SD_1="0.06959" SD_2="0.05178" SE="0.009490763235766952" STUDY_ID="STD-Hamer-2007" TOTAL_1="85" TOTAL_2="81" WEIGHT="30.08808709009102"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.91848898032766" CI_END="0.23704097113799819" CI_START="0.12856307594990504" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.18280202354395161" ESTIMABLE="YES" I2="59.33710519634499" I2_Q="79.35547773359205" ID="CMP-001.07" MODIFIED="2011-06-25 17:22:30 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.08549957842759393" P_Q="0.02774419985186216" P_Z="3.9568442576667844E-11" Q="4.843899931882488" RANDOM="NO" SCALE="0.7" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="322" TOTAL_2="318" UNITS="" WEIGHT="100.0" Z="6.605684629591056">
<NAME>Maternal hemoglobin in g/dl</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 2-dose SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Monthly SP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.07458904844517297" CI_END="0.17943210452516065" CI_START="-0.08660954368997795" DF="1" EFFECT_SIZE="0.04641128041759135" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" MODIFIED="2011-06-25 15:12:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7847687001695611" P_Z="0.4940786891703727" STUDIES="2" TAU2="0.0" TOTAL_1="237" TOTAL_2="237" WEIGHT="16.625826356166627" Z="0.6838360738263686">
<NAME>Primigravidae and secundigravidae</NAME>
<CONT_DATA CI_END="0.5069329652185177" CI_START="-0.30693296521851493" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="9.7" MODIFIED="2011-06-24 11:15:37 +0100" MODIFIED_BY="[Empty name]" ORDER="474" SD_1="1.41" SD_2="1.83" SE="0.2076226749207392" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="118" WEIGHT="1.7765472490595904"/>
<CONT_DATA CI_END="0.18075329458877176" CI_START="-0.10075329458877347" EFFECT_SIZE="0.03999999999999915" ESTIMABLE="YES" MEAN_1="11.25" MEAN_2="11.21" MODIFIED="2011-06-25 15:12:02 +0100" MODIFIED_BY="[Empty name]" ORDER="475" SD_1="0.71" SD_2="0.16" SE="0.07181422500567186" STUDY_ID="STD-Hamer-2007" TOTAL_1="102" TOTAL_2="119" WEIGHT="14.849279107107037"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.26940123617857314" CI_START="0.150598763821425" DF="0" EFFECT_SIZE="0.20999999999999908" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" MODIFIED="2011-06-25 15:14:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.237617006371828E-12" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="81" WEIGHT="83.37417364383337" Z="6.929021401441313">
<NAME>Multigravidae (greater than 2 pregnancies)</NAME>
<CONT_DATA CI_END="0.26940123617857314" CI_START="0.150598763821425" EFFECT_SIZE="0.20999999999999908" ESTIMABLE="YES" MEAN_1="11.62" MEAN_2="11.41" MODIFIED="2011-06-25 15:14:21 +0100" MODIFIED_BY="[Empty name]" ORDER="476" SD_1="0.19" SD_2="0.2" SE="0.030307310056268084" STUDY_ID="STD-Hamer-2007" TOTAL_1="85" TOTAL_2="81" WEIGHT="83.37417364383337"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-09-02 09:24:12 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Monthly sulfadoxine pyrimethamine (SP) compared to standard 2-dose SP - Best-case scenario</NAME>
<DICH_OUTCOME CHI2="31.09567608564011" CI_END="1.164315063058554" CI_START="0.37838117934347615" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6637431029302447" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="241" I2="93.56823760804612" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.06607051608107548" LOG_CI_START="-0.42207047351377175" LOG_EFFECT_SIZE="-0.17799997871634812" METHOD="MH" MODIFIED="2011-09-02 09:24:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.7687545783573455E-7" P_Q="0.6451688001425109" P_Z="0.15289026084095916" Q="0.21204560036174624" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.22847467483716263" TOTALS="YES" TOTAL_1="359" TOTAL_2="363" WEIGHT="100.0" Z="1.4293966496134676">
<NAME>Maternal anaemia: haemoglobin less than 11 g/dl.</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="22.769076626926132" CI_END="1.5465271408442556" CI_START="0.3222516350683414" DF="1" EFFECT_SIZE="0.7059538935473254" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="185" I2="95.60807837583792" ID="CMP-002.01.01" LOG_CI_END="0.18935754607567662" LOG_CI_START="-0.49180487040789767" LOG_EFFECT_SIZE="-0.15122366216611055" MODIFIED="2011-06-24 11:19:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.8268347796723816E-6" P_Z="0.3841603809951778" STUDIES="2" TAU2="0.3064290280960121" TOTAL_1="254" TOTAL_2="263" WEIGHT="67.9112265829753" Z="0.8702562686471307">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="1.1196980906527403" CI_START="0.8736131621121912" EFFECT_SIZE="0.989031339031339" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="104" LOG_CI_END="0.04910093763546976" LOG_CI_START="-0.058680831381973754" LOG_EFFECT_SIZE="-0.004789946873251985" MODIFIED="2011-06-24 11:19:43 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.0633115446492076" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="131" VAR="0.004008351685868608" WEIGHT="35.36506883859382"/>
<DICH_DATA CI_END="0.6685100864755289" CI_START="0.3635640553824033" EFFECT_SIZE="0.49299719887955185" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="81" LOG_CI_END="-0.17489203572044498" LOG_CI_START="-0.43941906087564175" LOG_EFFECT_SIZE="-0.30715554829804337" MODIFIED="2011-06-24 11:19:57 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.15538448400605534" STUDY_ID="STD-Hamer-2007" TOTAL_1="119" TOTAL_2="132" VAR="0.024144337869828066" WEIGHT="32.54615774438149"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8014658815551585" CI_START="0.4171748733671796" DF="0" EFFECT_SIZE="0.5782312925170068" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="56" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-0.09611496085532753" LOG_CI_START="-0.37968185721243924" LOG_EFFECT_SIZE="-0.23789840903388337" MODIFIED="2011-06-24 11:20:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0010067876948090149" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="100" WEIGHT="32.08877341702469" Z="3.28862303516971">
<NAME>Multigravidae (greater than 2 pregnancies)</NAME>
<DICH_DATA CI_END="0.8014658815551585" CI_START="0.4171748733671796" EFFECT_SIZE="0.5782312925170068" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="56" LOG_CI_END="-0.09611496085532753" LOG_CI_START="-0.37968185721243924" LOG_EFFECT_SIZE="-0.23789840903388337" MODIFIED="2011-06-24 11:20:07 +0100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.16656859859894266" STUDY_ID="STD-Hamer-2007" TOTAL_1="105" TOTAL_2="100" VAR="0.027745098039215682" WEIGHT="32.08877341702469"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.206695270370821" CI_END="0.7677531678419991" CI_START="0.24405078282352075" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.43286344454929176" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="107" I2="67.77673282032244" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.11477838292988023" LOG_CI_START="-0.6125197949511596" LOG_EFFECT_SIZE="-0.3636490889405199" METHOD="MH" MODIFIED="2011-09-02 09:23:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0448986811983243" P_Q="0.4007060540047912" P_Z="0.004184691075992662" Q="0.7062078355394186" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.17288140759484635" TOTALS="YES" TOTAL_1="359" TOTAL_2="363" WEIGHT="100.0" Z="2.863893178748611">
<NAME>Low Birth Weight: birth weight less than 2.5 kg</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.156969291128554" CI_END="1.0516889312456514" CI_START="0.22798409249399235" DF="1" EFFECT_SIZE="0.4896614611913179" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="77" I2="75.94401281399614" ID="CMP-002.02.01" LOG_CI_END="0.021887303105919218" LOG_CI_START="-0.6420954546797868" LOG_EFFECT_SIZE="-0.3101040757869338" MODIFIED="2011-06-24 11:20:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.041463655182375714" P_Z="0.067138044911065" STUDIES="2" TAU2="0.23292131682795286" TOTAL_1="254" TOTAL_2="263" WEIGHT="70.18266673315203" Z="1.830748804467085">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="1.0622237383752444" CI_START="0.4569260307743439" EFFECT_SIZE="0.69667616334283" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="39" LOG_CI_END="0.02621600272252751" LOG_CI_START="-0.34015409976957117" LOG_EFFECT_SIZE="-0.15696904852352184" MODIFIED="2011-06-24 11:20:36 +0100" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.21520761176511485" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="131" VAR="0.0463143161616444" WEIGHT="38.99874915335351"/>
<DICH_DATA CI_END="0.5990748140479769" CI_START="0.17210403601268467" EFFECT_SIZE="0.32109685979655017" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="38" LOG_CI_END="-0.22251893837977169" LOG_CI_START="-0.7642089449107604" LOG_EFFECT_SIZE="-0.49336394164526604" MODIFIED="2011-06-24 11:20:50 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.3181913912450803" STUDY_ID="STD-Hamer-2007" TOTAL_1="119" TOTAL_2="132" VAR="0.10124576146247974" WEIGHT="31.183917579798525"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.614961554128597" CI_START="0.1638818760057492" DF="0" EFFECT_SIZE="0.31746031746031744" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="30" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-0.21115203438997124" LOG_CI_START="-0.7854690731892298" LOG_EFFECT_SIZE="-0.49831055378960054" MODIFIED="2011-06-24 11:21:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="6.71016794100207E-4" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="100" WEIGHT="29.81733326684796" Z="3.4011553638937153">
<NAME>Multigravidae</NAME>
<DICH_DATA CI_END="0.614961554128597" CI_START="0.1638818760057492" EFFECT_SIZE="0.31746031746031744" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="30" LOG_CI_END="-0.21115203438997124" LOG_CI_START="-0.7854690731892298" LOG_EFFECT_SIZE="-0.49831055378960054" MODIFIED="2011-06-24 11:21:01 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.33735667150587645" STUDY_ID="STD-Hamer-2007" TOTAL_1="105" TOTAL_2="100" VAR="0.11380952380952382" WEIGHT="29.81733326684796"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5500846057341162" CI_END="0.36178676470677057" CI_START="0.10296345512042329" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19300470282106783" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.44154732503826927" LOG_CI_START="-0.9873168923414588" LOG_EFFECT_SIZE="-0.7144321086898641" METHOD="MH" MODIFIED="2011-06-25 17:23:50 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4582832219864643" P_Q="0.4599702994853747" P_Z="2.8770577644738846E-7" Q="0.5459671606050512" RANDOM="YES" SCALE="46.83" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="359" TOTAL_2="363" WEIGHT="100.0" Z="5.131327528393522">
<NAME>Neonatal mortality</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.4315269675537504" CI_START="0.040575535549321536" DF="0" EFFECT_SIZE="0.13232323232323231" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="22" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-0.3649920585957702" LOG_CI_START="-1.391735739287801" LOG_EFFECT_SIZE="-0.8783638989417857" MODIFIED="2011-06-24 11:21:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="7.981374822276867E-4" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="131" WEIGHT="28.254950670290892" Z="3.3534398888839285">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="0.4315269675537503" CI_START="0.040575535549321536" EFFECT_SIZE="0.13232323232323231" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="22" LOG_CI_END="-0.36499205859577033" LOG_CI_START="-1.391735739287801" LOG_EFFECT_SIZE="-0.8783638989417857" MODIFIED="2011-06-24 11:21:37 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.6031143205016871" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="131" VAR="0.3637468835942118" WEIGHT="28.254950670290892"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.4702154921690231" CI_START="0.10664967227957661" DF="0" EFFECT_SIZE="0.22393822393822393" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="37" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-0.32770306629427387" LOG_CI_START="-0.9720404747423552" LOG_EFFECT_SIZE="-0.6498717705183146" MODIFIED="2011-06-24 11:21:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="7.698499098521231E-5" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="232" WEIGHT="71.7450493297091" Z="3.95359713120803">
<NAME>Primigravidae, secundigravidae and multigravidae women</NAME>
<DICH_DATA CI_END="0.4702154921690231" CI_START="0.10664967227957661" EFFECT_SIZE="0.22393822393822393" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="37" LOG_CI_END="-0.32770306629427387" LOG_CI_START="-0.9720404747423552" LOG_EFFECT_SIZE="-0.6498717705183146" MODIFIED="2011-06-24 11:21:50 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.37848698324401475" STUDY_ID="STD-Hamer-2007" TOTAL_1="224" TOTAL_2="232" VAR="0.1432523964851551" WEIGHT="71.7450493297091"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.883432104668422" CI_END="0.39202882335131517" CI_START="0.05158933765009141" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1422128944098918" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="90" I2="59.04519696120979" I2_Q="11.710410345474052" ID="CMP-002.04" LOG_CI_END="-0.4066820009330186" LOG_CI_START="-1.2874400479506298" LOG_EFFECT_SIZE="-0.8470610244418243" METHOD="MH" MODIFIED="2011-09-02 09:23:53 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0870114583850724" P_Q="0.2872137353720392" P_Z="1.6327698609500644E-4" Q="1.1326363662046282" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.476004291105272" TOTALS="YES" TOTAL_1="359" TOTAL_2="363" WEIGHT="100.0" Z="3.7699549978233264">
<NAME>Placental parasitaemia: presence of malaria in the placental blood</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2712541717339207" CI_END="0.5718372630630014" CI_START="0.06135014903138578" DF="1" EFFECT_SIZE="0.18730269968853863" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="63" I2="55.97146226762547" ID="CMP-002.04.01" LOG_CI_END="-0.24272754779693217" LOG_CI_START="-1.2121843779503452" LOG_EFFECT_SIZE="-0.7274559628736387" MODIFIED="2011-06-24 11:22:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13179332358578721" P_Z="0.0032671637236917827" STUDIES="2" TAU2="0.3980327107394466" TOTAL_1="254" TOTAL_2="263" WEIGHT="73.05904948311046" Z="2.9414151166393103">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="0.5255856805810966" CI_START="0.15012385460795935" EFFECT_SIZE="0.28089668615984403" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="38" LOG_CI_END="-0.2793564755055974" LOG_CI_START="-0.8235502930900567" LOG_EFFECT_SIZE="-0.551453384297827" MODIFIED="2011-06-24 11:22:16 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.31966214225195355" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="131" VAR="0.10218388518910818" WEIGHT="46.29341692580032"/>
<DICH_DATA CI_END="0.366687141743796" CI_START="0.021475250201279158" EFFECT_SIZE="0.08873949579831933" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="25" LOG_CI_END="-0.4357043187484897" LOG_CI_START="-1.6680617676409848" LOG_EFFECT_SIZE="-1.0518830431947372" MODIFIED="2011-06-24 11:22:27 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.7238928657472076" STUDY_ID="STD-Hamer-2007" TOTAL_1="119" TOTAL_2="132" VAR="0.5240208810797047" WEIGHT="26.76563255731013"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.28894663235495593" CI_START="0.01722408768323442" DF="0" EFFECT_SIZE="0.07054673721340388" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="27" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-0.5391823628282697" LOG_CI_START="-1.763863772301619" LOG_EFFECT_SIZE="-1.1515230675649442" MODIFIED="2011-06-24 11:22:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="2.28016970544634E-4" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="100" WEIGHT="26.940950516889544" Z="3.685764676978203">
<NAME>Multigravidae (greater than 2 pregnancies)</NAME>
<DICH_DATA CI_END="0.28894663235495593" CI_START="0.01722408768323442" EFFECT_SIZE="0.07054673721340388" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="27" LOG_CI_END="-0.5391823628282697" LOG_CI_START="-1.763863772301619" LOG_EFFECT_SIZE="-1.1515230675649442" MODIFIED="2011-06-24 11:22:39 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.7193839221953932" STUDY_ID="STD-Hamer-2007" TOTAL_1="105" TOTAL_2="100" VAR="0.5175132275132275" WEIGHT="26.940950516889544"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.306876187620827" CI_END="0.32621622274339857" CI_START="0.03987340827000898" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.11404978138404177" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="108" I2="53.56263071252055" I2_Q="32.5466016953326" ID="CMP-002.05" LOG_CI_END="-0.48649444527995134" LOG_CI_START="-1.399316640445092" LOG_EFFECT_SIZE="-0.9429055428625217" METHOD="MH" MODIFIED="2011-09-02 09:23:59 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.11608443355316878" P_Q="0.22338334309272934" P_Z="5.141173482007105E-5" Q="1.4825049962394639" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4701388997675647" TOTALS="YES" TOTAL_1="359" TOTAL_2="363" WEIGHT="99.99999999999999" Z="4.04911474462865">
<NAME>Maternal peripheral parasitaemia</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8250771258358742" CI_END="0.40064101628666277" CI_START="0.06020678334829279" DF="1" EFFECT_SIZE="0.15531035660254905" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="84" I2="45.20779501074476" ID="CMP-002.05.01" LOG_CI_END="-0.39724459115050675" LOG_CI_START="-1.2203545751081462" LOG_EFFECT_SIZE="-0.8087995831293264" MODIFIED="2011-06-24 11:23:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.17671028172902314" P_Z="1.1726378466834663E-4" STUDIES="2" TAU2="0.24957667056812666" TOTAL_1="254" TOTAL_2="263" WEIGHT="80.73376927337046" Z="3.8517770031715983">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="0.37675980829274436" CI_START="0.11897277738577085" EFFECT_SIZE="0.21171717171717172" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="55" LOG_CI_END="-0.42393543275727624" LOG_CI_START="-0.9245523998144455" LOG_EFFECT_SIZE="-0.6742439162858609" MODIFIED="2011-06-24 11:22:58 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.29406488454333435" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="131" VAR="0.08647415632148456" WEIGHT="51.65283911913239"/>
<DICH_DATA CI_END="0.3137511586681095" CI_START="0.018652308799650984" EFFECT_SIZE="0.07649956534337873" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="29" LOG_CI_END="-0.5034146616790739" LOG_CI_START="-1.7292674031642379" LOG_EFFECT_SIZE="-1.1163410324216558" MODIFIED="2011-06-24 11:23:06 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.7200719684173202" STUDY_ID="STD-Hamer-2007" TOTAL_1="119" TOTAL_2="132" VAR="0.5185036397003943" WEIGHT="29.080930154238075"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.28785476342553556" CI_START="0.0054704807970415706" DF="0" EFFECT_SIZE="0.03968253968253969" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="24" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="-0.5408265794368886" LOG_CI_START="-2.2619745021261997" LOG_EFFECT_SIZE="-1.401400540781544" MODIFIED="2011-06-24 11:23:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0014143776851213846" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="100" WEIGHT="19.266230726629534" Z="3.1917007848518266">
<NAME>Multigravidae (greater than 2 pregnancies)</NAME>
<DICH_DATA CI_END="0.28785476342553556" CI_START="0.0054704807970415706" EFFECT_SIZE="0.03968253968253968" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="24" LOG_CI_END="-0.5408265794368886" LOG_CI_START="-2.2619745021261997" LOG_EFFECT_SIZE="-1.4014005407815442" MODIFIED="2011-06-24 11:23:14 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="1.0110108096073243" STUDY_ID="STD-Hamer-2007" TOTAL_1="105" TOTAL_2="100" VAR="1.0221428571428572" WEIGHT="19.266230726629534"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-09-02 09:24:54 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Monthly sulfadoxine pyrimethamine (SP) compared to standard 2-dose SP - worst-case scenario</NAME>
<DICH_OUTCOME CHI2="5.9925260784960015" CI_END="1.6587639392580762" CI_START="1.0495654697907286" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.319462524355778" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="183" I2="66.62509309426387" I2_Q="69.2379464527508" ID="CMP-003.01" LOG_CI_END="0.21978458543838686" LOG_CI_START="0.021009534182854034" LOG_EFFECT_SIZE="0.12039705981062042" METHOD="MH" MODIFIED="2011-09-02 09:24:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04997359081069708" P_Q="0.07139048071026144" P_Z="0.017583169452120743" Q="3.2507582709458682" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.026905981722346397" TOTALS="YES" TOTAL_1="359" TOTAL_2="363" WEIGHT="100.0" Z="2.3742808726028457">
<NAME>Maternal anaemia: haemoglobin less than 11g/dl.</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5246462946958206" CI_END="1.4161694290762172" CI_START="1.013115966293693" DF="1" EFFECT_SIZE="1.1978079393517724" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="148" I2="34.411016936914656" ID="CMP-003.01.01" LOG_CI_END="0.15111521501409966" LOG_CI_START="0.0056591597125983635" LOG_EFFECT_SIZE="0.078387187363349" MODIFIED="2011-06-24 11:25:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.21691814533051157" P_Z="0.03464581775007911" STUDIES="2" TAU2="0.005624069880466209" TOTAL_1="254" TOTAL_2="263" WEIGHT="73.95605347902777" Z="2.112473953223887">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="1.3051121080124997" CI_START="0.9789402412747901" EFFECT_SIZE="1.1303215303215304" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="91" LOG_CI_END="0.11564781880075324" LOG_CI_START="-0.009243818591883635" LOG_EFFECT_SIZE="0.05320200010443481" MODIFIED="2011-06-24 11:24:52 +0100" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.07336196602801061" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="131" VAR="0.0053819780594949835" WEIGHT="42.22390042194155"/>
<DICH_DATA CI_END="1.7213290804872594" CI_START="1.0474625483727429" EFFECT_SIZE="1.3427686864219373" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="57" LOG_CI_END="0.2358639058751866" LOG_CI_START="0.02013850388097952" LOG_EFFECT_SIZE="0.12800120487808306" MODIFIED="2011-06-24 11:25:06 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.1267181689893593" STUDY_ID="STD-Hamer-2007" TOTAL_1="119" TOTAL_2="132" VAR="0.016057494352015825" WEIGHT="31.732153057086222"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2690355672764952" CI_START="1.2142376071863499" DF="0" EFFECT_SIZE="1.6598639455782314" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="35" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.3558413035318526" LOG_CI_START="0.08430367964925406" LOG_EFFECT_SIZE="0.22007249159055334" MODIFIED="2011-06-24 11:25:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0014881972720198918" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="100" WEIGHT="26.043946520972234" Z="3.176975266543315">
<NAME>Multigravidae (greater than 2 pregnancies)</NAME>
<DICH_DATA CI_END="2.2690355672764952" CI_START="1.2142376071863499" EFFECT_SIZE="1.6598639455782314" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="35" LOG_CI_END="0.3558413035318526" LOG_CI_START="0.08430367964925406" LOG_EFFECT_SIZE="0.22007249159055334" MODIFIED="2011-06-24 11:25:17 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.1595025444015545" STUDY_ID="STD-Hamer-2007" TOTAL_1="105" TOTAL_2="100" VAR="0.025441061670569864" WEIGHT="26.043946520972234"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.237199148439995" CI_END="4.280312674840336" CI_START="0.8487998174931962" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9060767605787265" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="54" I2="83.65639084777858" I2_Q="90.33111138981606" ID="CMP-003.02" LOG_CI_END="0.6314754951808966" LOG_CI_START="-0.07119472248761385" LOG_EFFECT_SIZE="0.2801403863466414" METHOD="MH" MODIFIED="2011-09-02 09:24:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0022015454736662443" P_Q="0.0013000685764268383" P_Z="0.11810060870750447" Q="10.342450309611907" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4223855724015148" TOTALS="YES" TOTAL_1="359" TOTAL_2="363" WEIGHT="100.0" Z="1.5627959006897278">
<NAME>Low Birth Weight: birth weight less than 2.5 kg</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1676976970061692" CI_END="1.8229671951163746" CI_START="0.8622123216960214" DF="1" EFFECT_SIZE="1.2537084101484577" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="47" I2="14.361396570030506" ID="CMP-003.02.01" LOG_CI_END="0.26077885345578444" LOG_CI_START="-0.06438577502614275" LOG_EFFECT_SIZE="0.09819653921482087" MODIFIED="2011-06-24 11:26:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2798748586126343" P_Z="0.2365002107278219" STUDIES="2" TAU2="0.010502698508245435" TOTAL_1="254" TOTAL_2="263" WEIGHT="70.25484178064266" Z="1.183779928130904">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="1.6831175776072116" CI_START="0.6488285707497643" EFFECT_SIZE="1.045014245014245" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="26" LOG_CI_END="0.22611445556132606" LOG_CI_START="-0.18787003449700723" LOG_EFFECT_SIZE="0.019122210532159397" MODIFIED="2011-06-24 11:25:48 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.2431765387165407" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="131" VAR="0.05913482898215723" WEIGHT="35.38047056893208"/>
<DICH_DATA CI_END="2.535633402981831" CI_START="0.9253901695680478" EFFECT_SIZE="1.531812725090036" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="21" LOG_CI_END="0.40408646428432693" LOG_CI_START="-0.03367511832761507" LOG_EFFECT_SIZE="0.1852056729783559" MODIFIED="2011-06-24 11:26:07 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.25714332058103684" STUDY_ID="STD-Hamer-2007" TOTAL_1="119" TOTAL_2="132" VAR="0.06612268731944188" WEIGHT="34.87437121171059"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.764133770073904" CI_START="2.3542343045039056" DF="0" EFFECT_SIZE="5.034013605442177" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="7" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="1.0319790862715712" LOG_CI_START="0.371849683694029" LOG_EFFECT_SIZE="0.7019143849828001" MODIFIED="2011-06-24 11:26:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="3.072135471981713E-5" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="100" WEIGHT="29.745158219357336" Z="4.168052231653992">
<NAME>Multigravidae</NAME>
<DICH_DATA CI_END="10.764133770073904" CI_START="2.3542343045039056" EFFECT_SIZE="5.034013605442177" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="7" LOG_CI_END="1.0319790862715712" LOG_CI_START="0.371849683694029" LOG_EFFECT_SIZE="0.7019143849828001" MODIFIED="2011-06-24 11:26:26 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.38776327876729166" STUDY_ID="STD-Hamer-2007" TOTAL_1="105" TOTAL_2="100" VAR="0.15036036036036035" WEIGHT="29.745158219357336"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.538107967198645" CI_END="100.84177579304385" CI_START="0.04860617267316153" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.213940551791066" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="12" I2="94.88179714392592" I2_Q="94.69153256911152" ID="CMP-003.03" LOG_CI_END="2.0036404848656684" LOG_CI_START="-1.3133085746128943" LOG_EFFECT_SIZE="0.3451659551263871" METHOD="MH" MODIFIED="2011-06-24 11:27:07 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="9.861443343472942E-6" P_Q="1.4231886746873812E-5" P_Z="0.6833377618404024" Q="18.837828676903612" RANDOM="YES" SCALE="46.83" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="7.204075283837658" TOTALS="YES" TOTAL_1="359" TOTAL_2="363" WEIGHT="100.00000000000001" Z="0.4079127105096016">
<NAME>Neonatal mortality</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1684204105292981" CI_START="0.08954336481470301" DF="0" EFFECT_SIZE="0.3234567901234568" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.0675991348325157" LOG_CI_START="-1.047966589950324" LOG_EFFECT_SIZE="-0.49018372755890427" MODIFIED="2011-06-24 11:26:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0849914855942017" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="131" WEIGHT="49.73135675856363" Z="1.7224309253676078">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="1.1684204105292981" CI_START="0.08954336481470301" EFFECT_SIZE="0.3234567901234568" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.0675991348325157" LOG_CI_START="-1.047966589950324" LOG_EFFECT_SIZE="-0.49018372755890427" MODIFIED="2011-06-24 11:26:52 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.6552888288768377" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="131" VAR="0.42940344925077745" WEIGHT="49.73135675856363"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="47.16177046550142" CI_START="4.6728757620648675" DF="0" EFFECT_SIZE="14.845238095238093" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="3" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="1.673590100260309" LOG_CI_START="0.6695842345730126" LOG_EFFECT_SIZE="1.171587167416661" MODIFIED="2011-06-24 11:27:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.780119380682255E-6" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="232" WEIGHT="50.268643241436386" Z="4.57421362038365">
<NAME>Primigravidae, secundigravidae and multigravidae women</NAME>
<DICH_DATA CI_END="47.16177046550142" CI_START="4.6728757620648675" EFFECT_SIZE="14.845238095238095" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="3" LOG_CI_END="1.673590100260309" LOG_CI_START="0.6695842345730126" LOG_EFFECT_SIZE="1.171587167416661" MODIFIED="2011-06-24 11:27:07 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.5897580154139067" STUDY_ID="STD-Hamer-2007" TOTAL_1="224" TOTAL_2="232" VAR="0.3478145167449498" WEIGHT="50.268643241436386"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="31.92526147273742" CI_END="30.01653426604711" CI_START="0.35068412273930893" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.244429377681557" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="33" I2="93.73536845827276" I2_Q="72.06420289447715" ID="CMP-003.04" LOG_CI_END="1.477360546800622" LOG_CI_START="-0.4550838964019267" LOG_EFFECT_SIZE="0.5111383251993475" METHOD="MH" MODIFIED="2011-09-02 09:24:47 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.1682256662037815E-7" P_Q="0.05849211028510959" P_Z="0.29981292461613607" Q="3.5796365366725196" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.475270741973306" TOTALS="YES" TOTAL_1="359" TOTAL_2="363" WEIGHT="100.0" Z="1.0368346805857835">
<NAME>Placental parasitaemia: presence of malaria in the placental blood</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="20.55686595077704" CI_END="14.395353805471423" CI_START="0.13373873619029356" DF="1" EFFECT_SIZE="1.387521684499338" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="32" I2="95.13544524542566" ID="CMP-003.04.01" LOG_CI_END="1.1582223433284207" LOG_CI_START="-0.8737427851302492" LOG_EFFECT_SIZE="0.14223977909908567" MODIFIED="2011-06-24 11:27:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.788628822500641E-6" P_Z="0.7837778267625349" STUDIES="2" TAU2="2.710864005034293" TOTAL_1="254" TOTAL_2="263" WEIGHT="71.31191334865422" Z="0.2743992407139496">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="0.8320206924025441" CI_START="0.2191019687451647" EFFECT_SIZE="0.426962962962963" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="25" LOG_CI_END="-0.07986587264618387" LOG_CI_START="-0.659353720059925" LOG_EFFECT_SIZE="-0.3696097963530544" MODIFIED="2011-06-24 11:27:30 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.34039403008193897" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="131" VAR="0.11586809571542397" WEIGHT="35.88038069304247"/>
<DICH_DATA CI_END="10.098395013752222" CI_START="2.0912285560201225" EFFECT_SIZE="4.595438175270108" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="7" LOG_CI_END="1.0042523547668314" LOG_CI_START="0.32040150062920547" LOG_EFFECT_SIZE="0.6623269276980184" MODIFIED="2011-06-24 11:27:42 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.40169737683676393" STUDY_ID="STD-Hamer-2007" TOTAL_1="119" TOTAL_2="132" VAR="0.16136078255753714" WEIGHT="35.43153265561175"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="192.32391335805818" CI_START="3.697465898518835" DF="0" EFFECT_SIZE="26.66666666666667" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="1" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="2.2840332873261775" LOG_CI_START="0.5679041772183849" LOG_EFFECT_SIZE="1.4259687322722812" MODIFIED="2011-06-24 11:27:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0011253584105467207" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="100" WEIGHT="28.688086651345788" Z="3.257152788648124">
<NAME>Multigravidae (greater than 2 pregnancies)</NAME>
<DICH_DATA CI_END="192.32391335805818" CI_START="3.697465898518835" EFFECT_SIZE="26.666666666666668" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="1" LOG_CI_END="2.2840332873261775" LOG_CI_START="0.5679041772183849" LOG_EFFECT_SIZE="1.4259687322722812" MODIFIED="2011-06-24 11:27:56 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="1.0080627342534176" STUDY_ID="STD-Hamer-2007" TOTAL_1="105" TOTAL_2="100" VAR="1.0161904761904763" WEIGHT="28.688086651345788"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="36.47163064360364" CI_END="20.14606468275484" CI_START="0.24541783235670614" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.223556503657977" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="52" I2="94.51628576867385" I2_Q="77.66537297213294" ID="CMP-003.05" LOG_CI_END="1.3041902240017391" LOG_CI_START="-0.6100938840998547" LOG_EFFECT_SIZE="0.3470481699509423" METHOD="MH" MODIFIED="2011-09-02 09:24:54 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.2030665907936111E-8" P_Q="0.03434693014011114" P_Z="0.4772953838566074" Q="4.477352582392776" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.4198688331772247" TOTALS="YES" TOTAL_1="359" TOTAL_2="363" WEIGHT="100.00000000000001" Z="0.7106593124036772">
<NAME>Maternal peripheral parasitaemia</NAME>
<GROUP_LABEL_1>Monthly SP</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard 2-dose SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Monthly SP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2-dose SP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="23.426135550370567" CI_END="8.565381004331462" CI_START="0.08993876691883809" DF="1" EFFECT_SIZE="0.8777014331306578" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="51" I2="95.73126349478423" ID="CMP-003.05.01" LOG_CI_END="0.9327466859703576" LOG_CI_START="-1.0460530710044054" LOG_EFFECT_SIZE="-0.05665319251702396" MODIFIED="2011-06-24 11:28:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.2980715661248254E-6" P_Z="0.910642750938192" STUDIES="2" TAU2="2.586990582158663" TOTAL_1="254" TOTAL_2="263" WEIGHT="71.53518964047038" Z="0.112227845744573">
<NAME>Primigravidae and secundigravidae</NAME>
<DICH_DATA CI_END="0.5025677120800589" CI_START="0.15294820416934451" EFFECT_SIZE="0.27724867724867724" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="42" LOG_CI_END="-0.2988054164913456" LOG_CI_START="-0.8154556178876894" LOG_EFFECT_SIZE="-0.5571305171895174" MODIFIED="2011-06-24 11:28:13 +0100" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.30348288575995547" STUDY_ID="STD-Filler-2006" TOTAL_1="135" TOTAL_2="131" VAR="0.09210186194919019" WEIGHT="36.00286886084724"/>
<DICH_DATA CI_END="5.880550964396283" CI_START="1.3664903673032278" EFFECT_SIZE="2.834733893557423" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="9" LOG_CI_END="0.7694180181828145" LOG_CI_START="0.13560657460035974" LOG_EFFECT_SIZE="0.45251229639158713" MODIFIED="2011-06-24 11:28:22 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.37230397937757925" STUDY_ID="STD-Hamer-2007" TOTAL_1="119" TOTAL_2="132" VAR="0.13861025306038094" WEIGHT="35.532320779623134"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="165.80434373310845" CI_START="3.150996939095945" DF="0" EFFECT_SIZE="22.857142857142854" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="1" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="2.219595903986323" LOG_CI_START="0.49844798129701257" LOG_EFFECT_SIZE="1.3590219426416679" MODIFIED="2011-06-24 11:28:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0019669137149687754" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="100" WEIGHT="28.46481035952964" Z="3.095183193336891">
<NAME>Multigravidae (greater than 2 pregnancies)</NAME>
<DICH_DATA CI_END="165.80434373310845" CI_START="3.150996939095945" EFFECT_SIZE="22.857142857142858" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="1" LOG_CI_END="2.219595903986323" LOG_CI_START="0.49844798129701257" LOG_EFFECT_SIZE="1.3590219426416679" MODIFIED="2011-06-24 11:28:32 +0100" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="1.0110108096073243" STUDY_ID="STD-Hamer-2007" TOTAL_1="105" TOTAL_2="100" VAR="1.0221428571428572" WEIGHT="28.46481035952964"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-09-02 09:07:54 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-09-02 09:07:54 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>